A Study of the Etiology, contributory factors and correlation of the clinical and laboratory profiles of anemia in elderly patients presenting at a tertiary hospital in rural South India by Joshila Nandhini, G
 
 
A STUDY OF THE ETIOLOGY, CONTRIBUTORY FACTORS AND 
CORRELATION OF THE CLINICAL AND LABORATORY PROFILES 
OF ANEMIA IN ELDERLY PATIENTS PRESENTING AT A TERTIARY 
HOSPITAL IN RURAL SOUTH INDIA 
 
 
DISSERTATION SUBMITTED TO 
In partial fulfillment of the requirement for the degree of 
DOCTOR OF MEDICINE IN PATHOLOGY 
(Branch III) M. D. (PATHOLOGY) 
 
of 
THE TAMIL NADU DR. M. G. R MEDICAL UNIVERSITY 
CHENNAI- 600032 
 
 
 
 
DEPARTMENT OF PATHOLOGY 
TIRUNELVELI MEDICAL COLLEGE 
TIRUNELVELI- 11 
 
APRIL 2016 
 
 
 
CERTIFICATE 
                                    
I hereby certify that this dissertation entitled  “A STUDY OF THE 
ETIOLOGY, CONTRIBUTORY FACTORS AND CORRELATION OF 
THE CLINICAL AND LABORATORY PROFILES OF ANEMIA IN 
ELDERLY PATIENTS PRESENTING AT A TERTIARY HOSPITAL IN 
RURAL SOUTH INDIA” is a record of  work done by Dr. G.JOSHILA 
NANDHINI in the Department of Pathology, Tirunelveli Medical College, 
Tirunelveli, during her postgraduate degree course period from 2013- 2016. This 
work has not formed the basis for previous award of any degree. 
 
 
 
Dr.Sithy Athiya Munavarah, M.D 
DEAN 
Tirunelveli Medical College, 
Tirunelveli – 11. 
                                                                      
                                            
 
 
 
 
 
 
 
 
 
CERTIFICATE 
 
This is to certify that the dissertation titled “A STUDY OF THE 
ETIOLOGY, CONTRIBUTORY FACTORS AND CORRELATION OF 
THE CLINICAL AND LABORATORY PROFILES OF ANEMIA IN 
ELDERLY PATIENTS PRESENTING AT A TERTIARY HOSPITAL IN 
RURAL SOUTH INDIA”, is a bonafide work done by Dr. G.JOSHILA 
NANDHINI, Post Graduate Student, Department of Pathology, Tirunelveli 
Medical College, Tirunelveli – 627011, in partial fulfillment of the university 
rules and regulations for the award of MD DEGREE in PATHOLOGY 
BRANCH-III, under our guidance and supervision, during the academic period 
from September 2013 to September 2015. 
 
 
 
Dr K. SHANTARAMAN, MD,
Professor and Head, 
Department of Pathology, 
Tirunelveli Medical College 
Tirunelveli- 627011 
 Dr. K. SHANTARAMAN, MD,
Professor and Head, 
Department of Pathology, 
Tirunelveli Medical College 
Tirunelveli- 627011. 
 
 
 
 
 
 
 
 
 
 
DECLARATION 
 
I solemnly declare that the dissertation titled “A STUDY OF THE 
ETIOLOGY, CONTRIBUTORY FACTORS AND CORRELATION OF 
THE CLINICAL AND LABORATORY PROFILES OF ANEMIA IN 
ELDERLY PATIENTS PRESENTING AT A TERTIARY HOSPITAL IN 
RURAL SOUTH INDIA” was done by me at Tirunelveli Medical College, 
Tirunelveli – 627011, during the period September 2013 to September 2015 under 
the guidance and supervision of Prof. K. SHANTARAMAN, MD, to be 
submitted to The Tamil Nadu Dr. M.G.R. Medical University towards the partial 
fulfillment of requirements for the award of MD DEGREE in PATHOLOGY 
BRANCH-III. 
 
Place : Tirunelveli 
Date :  
 
Dr. JOSHILA NANDHINI G,
MD PATHOLOGY, 
Post Graduate Student, 
Department of Pathology 
Tirunelveli Medical College, 
Tirunelveli – 627011. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ACKNOWLEDGEMENT 
 
I thank Professor Dr. SITHY ATHIA MUNAVARAH, M.D, Dean, 
Tirunelveli Medical College, for having permitted me to conduct the study and 
use the hospital resources in the study. 
I express my heartfelt gratitude to Professor Dr. SHANTARAMAN. K. MD, 
Professor and Head, Department of Pathology, for his inspiration, advice and 
guidance in making this work complete. 
I am extremely thankful to Professors Dr. VALLIMANALAN. S. M.D, DR. 
SWAMINATHAN .K. M.D., DR.SURESH DURAI. J. M.D., DR.ARASI 
RAJESH, M.D, DR.VASUKI, M.D, Additional Professors, Department of 
Pathology, for guiding me during the period of study. 
I am extremely thankful to Assistant Professors, Dr. Hidhaya Fathima M.D, 
Dr.Mahalakshmi M.D, Dr. Johnsy Merla M.D, Dr. Sindhuja M.D, Department of 
Pathology, for guiding me academically and professionally during the period of 
study. 
I also thank all the lab technicians especially Mr. Balamurugan and Mrs. 
Rajeshwari for their valued assistance and my fellow postgraduates for their 
cooperation which enormously helped me in the study. I am also indebted to thank 
all the patients and their caring relatives for without their humble cooperation, this 
study would not have been possible. 
 
Dr. JOSHILA NANDHINI G 
 
 
 
ABBREVIATIONS 
ACD               Anemia Of Chronic Disease 
ADAMTS            A Disintegrin and metalloproteinase with thrombospondin  
motifs 
AML                     Acute Myeloid Leukemia 
ATP                      Adenosine TriPhosphate 
AUE                      Anemia Of Unexplained Etiology 
A-CKD  Anemia of Chronic Kidney Disease 
CKI                       Chronic Kidney Injury 
CLL                      Chronic Lymphoid Leukemia 
CML                     Chronic Myeloid leukemia 
CoA                       Co enzyme A 
DIC                        Disseminated Intravascular Coagulation 
DMT                      Divalent Metal Transporter 
dTMP                    Thymidine mono phosphate 
EPO                      Erythropoietin 
FAD                       Flavin Adenine Diphosphate 
GI                          Gastro intestinal 
GIT                       Gastro Intestinal Tract 
G6PD                    Glucose 6 phosphate dehydrogenase 
HCT                      Hematocrit 
HE                         Hereditary Elliptocytosis 
HgB                       Hemoglobin 
HS                         Hereditary Spherocytosis 
IDA                       Iron Deficiency Anemia 
IFN                        Interferon 
IL                          Interleukin 
MAHA                Micro Angiopathic Hemolytic Anemia 
MCH                    Mean Corpuscular Hemoglobin 
MCHC                 Mean Corpuscular Hemoglobin Concentration 
MCV                    Mean Corpuscular Volume 
 
 
MDS                     MyeloDysplastic Syndrome 
NAD                     Nicotinamide adenine Diphosphate 
NCNC  Normocytic Normochromic 
NHANES             United Nations national Health And Nutritional Examination  
Survey 
Pg                         Picograms 
RBC                      Red Blood Cell 
RDW                     Red cell Distribution Width 
RNA                      Ribonucleic acid 
sTFR                     Soluble Transferrin Receptor 
TGF                      Tissue Growth Factor 
TNF                      Tissue Necrosis Factor 
TTP                      Thrombotic Thrombocytopenic Purpura 
vWF                     Von Willebrand Factor 
WBC                    White Blood Cell 
WHO                    World Health Organisation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE OF CONTENTS 
1.  INTRODUCTION 1 
2.  AIMS OF THE STUDY 2 
3.  REVIEW OF LITERATURE 3 
4.  MATERIALS AND METHODS 41 
5.  OBSERVATIONS AND RESULTS 44 
6.  DISCUSSION 72 
7.  LIMITATIONS 77 
8.  CONCLUSION 78 
9.  BIBLIOGRAPHY  
10.  ANNEXURES 
 PROFORMA  
 MASTER CHART  
 
 
 
 
 
 
 
 
 
 
ABSTRACT 
 
Background: Anemia is defined as a state of decreased oxygen carrying capacity 
of the blood wherein the hemoglobin is less than 13 g/ml in men and less than12 
g/ml in non pregnant women by WHO reference standards. The demographic 
transition with ageing of population is a global phenomenon and in recent years 
there has been an increasing international awareness of health issues relating to 
aging population. The prevalence of anemia among elderly Indians, as reported in 
Indian cross sectional studies is between 6 and 30 % among men and between 10 
and 20 % among women. Thus anemia represents an emerging global health 
problem producing a negative impact in the quality of life among the elderly and 
requiring greater allocation of health resources.  
Aims: To identify elderly patients with anemia and study the etiology, clinical 
parameters, laboratory parameters in these patients.  
Methods:  The cases received in the hematology department for peripheral smear 
reporting were screened and 100 cases that showed hemoglobin levels lower than 
standard WHO values were chosen. The entire medical history was obtained from 
each of the cases including previous medical reports and imaging studies. Blood 
samples were collected from all patients in plain vacutainers and EDTA 
containing vacutainers. Complete blood counts for all the samples was done using 
SYSMEX 3 part differential analyzer and the RBC indices was noted along with 
total WBC count, differential count, platelet count and hematocrit. ESR for all 
cases was done using Westergren tube. Peripheral smears were made for all the 
samples and stained using Leishman stain. Supravital staining using methylene 
blue was done for reticulocyte counting. Ferritin, iron and TIBC for all samples 
was done using SPINREACT kits for all the three and values obtained using 
colorimetric methods. The results obtained by the above tests was analyzed and 
the different etiologies, clinical features, intensity of anemia, peripheral smear 
picture and iron parameters  were studied and compared with other studies.  
Results: Among the etiologies, iron deficiency anemia was seen in 43% of 
patients, anemia of chronic disease in 32%, anemia of chronic kidney disease and 
unexplained anemia in 11 % each and 1 case β thalassemia. Among clinical 
features the commonest symptom was easy fatiguability and commonest sign was 
pallor. Peripheral smear study showed that normocytic normochromic anemia was 
commonest type.  
Conclusion: This study showed that the commonest cause for anemia among 
elderly patients is iron deficiency anemia followed by anemia due to chronic 
disease and also that it can be asymptomatic which is incidentally stumbled upon 
when one is evaluated for other symptoms. Not many clinical signs are consistent 
with anemia except for pallor even which can be absent in cases of mild anemia. 
Even though iron deficiency anemia is the commonest cause the peripheral smear 
studies in this study showed that normocytic normochromic picture was the 
commonest even when MCV levels were suggestive of microcytic anemia. 
Geriatric anemia is a disease that often goes unreported hence every effort should 
be made to identify the disease and evaluate the cause and it should not be ignored 
as merely being a part of ageing, for the consequences of anemia can have higher 
morbidity in the elderly.  
Key Words: Geriatric anemia, Anemia in elderly, Iron deficiency, Iron 
parameters, Peripheral smear. 
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INTRODUCTION 
 
Anemia is defined as a state of decreased oxygen carrying capacity of the 
blood wherein the hemoglobin is less than 13 g/ml in men and less than12 g/ml in 
non pregnant women by WHO reference standards [1].The demographic transition 
with ageing of population is a global phenomenon and in recent years there has 
been an increasing international awareness of health issues relating to aging 
population[5,6]. According to a 2004 report of the United States National Health 
and Nutritional Examination Survey  (NHANES) III, 10 % of Americans 65 years 
and older are anemic, rising to a 25 % of men and 20 % of women 85 years and 
older [3].The prevalence of anemia among elderly Indians , as reported in Indian 
cross sectional studies is between 6 and 30 % among men and between 10 and 20 
% among women [4].Thus anemia represents an emerging global health problem 
producing a negative impact in the quality of life among the elderly and requiring 
greater allocation of health resources[7]. 
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AIMS OF THE STUDY 
 
1. To identify elderly patients ( > 65 years of age ) with anemia based on 
WHO criteria,  
2. To study clinical features, etiology in those diagnosed with anemia, 
3. To analyse the laboratory parameters in these patients. 
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REVIEW OF LITERATURE 
 
Geriatric anemia is a unique clinical entity for several reasons. Firstly, its 
diagnosis poses a challenge because several features of anemia are easy to 
overlook [8]. The onset of symptoms and signs is usually insidious and many 
elderly patients adjust their activities as their bodies make physiological 
adaptations [8]. Secondly, in contrast to younger ages anemia is more common in 
elderly men than women with a high incidence occurring in men older than 85 
years[8].Thirdly, the etiology of geriatric anemia varies considerably from anemia 
in younger age [8]. 
ETIOLOGY: 
Anemia in the elderly is multifactorial with the most common causes being 
nutritional deficiencies including iron, B 12, folate deficiencies, anemia of chronic 
inflammation/ disease and chronic kidney disease [9, 10] and other less common 
causes being diseases of the marrow, hemolytic anemias and endocrinopathy. 
Most of the time despite a complete evaluation a significant number of cases have 
no etiology identified [9, 10]. 
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TABLE NO. 1.  CAUSES OF ANEMIA IN ELDERLY:[11] 
Cause Prevalence 
Iron deficiency 15 to 30 % 
Chronic disease/inflammation 30 to 45 % 
Chronic kidney disease 8% 
Post hemorrhagic 5 to 10 % 
Vitamin B12 or folate deficiencies 5 to 10 % 
Myelodysplastic syndromes 5% 
Chronic leukemia or lymphoma 5% 
Unexplained 14% to 45% 
 
Data from Joosten E, Pelemans W, Hiele M, et al. Prevalence and causes of 
anaemia in a geriatric hospitalized population. Gerontology. 1992; 38(1-2):111-7. 
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NUTRIENT DEFICIENT ANEMIAS: 
Nutrient deficient anemias are significant cause of anemia in the elderly. 
Iron, folate or vitamin B-12 deficiencies maybe seen, but mostly a combination of 
the three occurs [9]. 
ANEMIA DUE TO IRON DEFICIENCY 
IRON METABOLISM 
Iron is derived from diet either as heme iron contained in animal products 
or as non-heme iron in plant products like cereals, pulses and vegetables. Heme 
iron is absorbed better when compared to non heme iron. Iron in the body can be 
divided into storage and functional compartments. About 80% of the iron is in 
functional form as in hemoglobin, myoglobin and certain enzymes such as 
catalase and cytochromes, the remaining iron is stored in the body in the  form of 
ferritin and hemosiderin, which is a permanent non reusable form. 
Iron balance 
Dietary iron is absorbed in proximal duodenum. Luminal non heme iron is 
mostly in ferric state and must first be reduced to ferrous form by ferrireductases 
like b cytochromes[15]. Ferrous iron is then transferred across apical membrane by 
divalent metal transporter 1 (DMT 1). Heme iron is directly transported into 
enterocyte by a heme transporter. Iron can now be either circulated or stored. Iron 
that is destined for circulation is transported across the basolateral membrane by 
ferriportin, a process that is coupled to oxidation of ferrous iron to ferric form by 
hephastin and ceruloplasmin. Newly absorbed iron binds to transferrin and is 
rapidly delivered to erythroid progenitors. 
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Role of transferrin 
Transferrin is a glycoprotein with a molecular weight of approximately 80 
kD which has iron binding capacity, is synthesized by the liver and enables  
delivery of iron to cells including erythroid precursors[16]. The eythroid precursors 
have high affinity receptors for transferrin which mediate iron absorption through 
endocytosis[15]. 
Role of ferritin 
Ferritin is a ubiquitous protein that is found in highest levels in the liver, 
bone marrow and spleen[16]and serves to store iron as reusable, non toxic molecule 
while  free iron is ionized and hence highly toxic. Apoferritin, is an apoprotein 
present in the intestinal mucosa, that binds to free ferrous iron forms ferritin[17] 
and stores it in ferric state. Intracellular ferritin is located in cytosol and in 
lysosomes in which partially degraded protein shells of ferritin accumulate into 
hemosiderin granules. Under steady state conditions serum ferritin levels correlate 
with body iron stores so is the most effective way to diagnose anemia and when 
levels are below 16 ng/ml iron deficiency is highly likely [14]. 
Role of hepcidin 
It is a small circulating peptide that is synthesized and released from the 
liver in response to increases in intrahepatic iron levels and inhibits iron transfer 
from enterocyte and macrophages to plasma by binding to ferriportin causing it to 
be endocytosed and degraded[16]. As hepcidin levels increase, iron becomes 
trapped within duodenal cells in the form of mucosal ferritin and is lost as these 
cells get sloughed. 
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IRON DEFICIENCY 
An estimated 16 % of anemic elderly have iron deficiency [9] which occurs 
when the rate of iron utilization exceeds the rate of intestinal absorption and may 
be caused by 
1. inadequate intake 
2. impaired absorption 
3. increased requirement 
4. chronic blood loss 
Inadequate intake 
In the developing countries iron is mainly obtained in the non heme form 
from cereals, pulses, vegetables and fruits which is a poorly absorbed form of 
iron[16] in contrast to the Western world where most of the iron is in the heme 
form from animal products. Hence people in developing countries owing to their 
diet habits are at risk for iron deficiency where elderly are at an even further risk 
due to decreased intake of food and poor dentition[16]. 
Impaired absorption 
Iron absorption is defective in cases of celiac sprue, fat malabsorption 
syndromes, diarrhea, following gastrectomy etc[16]. Commonly used medications 
for acid peptic disease like antacids, proton pump inhibitors, H2 blockers also 
inhibit iron absorption by decreasing acid content in stomach. 
Chronic blood loss 
Iron deficiency in the elderly always leads to an evaluation of the 
gastrointestinal (GI) tract as a possible source of bleeding. 20 to 40 % of patients 
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have upper GI bleed from peptic ulcer disease, gastritis, esophagitis or gastric 
cancer [12], with 15 to 20 % cases having loss from the colon due to causes like 
angiodysplasia, polyps, colitis [12]. 
ANEMIA DUE TO VITAMIN B-12 DEFICIENCY 
Vitamin B -12 is a complex organo-metallic compound called cobalamin 
essential for DNA synthesis, maturation and normal functioning of the nervous 
system. Micro-organisms are the ultimate source of this vitamin, vegetarian diets 
are deficient in this vitamin. Vitamin B 12 acts as cofactor in conversion of 
homocysteine to methionine, a reaction which yields tetrahydrofolate through 
several steps. Tetrahydrofolate is essential since it is required for conversion of 
deoxyuridine phosphate to deoxythymidine monophosphate, an immediate 
precursor of DNA. Deficiency of vitamin B 12 causes reduced availability of 
tetrahydrofolate leading to impaired DNA synthesis. Anemia due to vitamin B 12 
and folate is termed megaloblastic anemia and is found to have an incidence of 14 
% according to NHANES III study [18]. 
PATHOGENESIS: 
ABSORPTION OF VITAMIN B-12 
This is done by the presence of a factor called the intrinsic factor which is 
secreted by the parietal cells of gastric fundic mucosa.B-12 from the diet gets 
bound to R- Binders, also called transcobalamin I or cobalophilin, in saliva. When 
it reaches the duodenum it gets dissociated from the R-binder and gets bound to 
intrinsic factor and remains bound till it reaches the ileum. In the ileum, it is 
endocytosed by ileal enterocytes and gets associated with a carrier protein 
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transcobalamin II and is secreted into the plasma which delivers B – 12 to the 
required sites rapidly. 
PERNICIOUS ANEMIA 
It is a disease of older adults uncommon in ages below 30 years with a 
suspected genetic predisposition and a prevalence of 0.1% in the general 
population and 1.9% in subjects over the age of 60 years[19]. It is due to 
autoimmune attack on the gastric mucosa and there are three types of 
autoantibodies are present[16]: 
Type I which blocks the binding of B-12 to intrinsic factor and is the cause 
in 75% of the patients, type II prevents binding of IF-B12 complex to ileal 
receptor and type III which acts against α and β subunits of gastric proton pump 
and is found in 90 % of persons not specific for pernicious anemia. The 
autoantibodies are of diagnostic utility, they are not the primary cause of gastric 
pathology. The autoreactive T-cell response initiates gastric mucosal injury and 
triggers formation of autoantibodies which further exacerbate epithelial injury and 
cause the mass of intrinsic factor secreting cells to fall below a threshold, when 
anemia develops. Pernicious anemia is found to be associated with other 
autoimmune diseases such as Hashimotos thyroiditis, type 1 diabetes mellitus [19]. 
OTHER CAUSES OF B-12 DEFICIENCY [16] 
1. Achlorhydria and loss of pepsin secretion. 
2. Following gastrectomy  IF is unavailable 
3. Loss of exocrine pancreatic function, B-12 cannot be released from R- 
binder complex. 
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4. Ileal resection can remove or damage the site of IF-B12 absorption 
5. Tapeworm infestation when present compete with the host for B 12 and 
induce deficiency 
6. In conditions like hyperthyroidism, disseminated cancer, chronic infections 
an increased demand for B12 can produce a relative deficiency. 
The vitamin B-12 levels have been used to estimate the prevalence of B-12 
deficiencies with a threshold of 200 pg/ml or 148pmol/L[20]. Unpublished data 
from the National Health and Nutrition Examination Survey (NHANES) 2001-
2004 stratified by age have estimated that 1 (3.2%) of every 31 adults 51 years of 
age or older in the United States will have a low vitamin B12 serum level (≤ 200 
pg/mL) and The Framingham study with a cohort of non institutionalized adults 
67 through 96 years of age found that 5.3% of the participants had serum vitamin 
B12 levels below 200 pg/mL[20]. 
ANEMIA DUE TO FOLATE DEFICIENCY 
Anemia due to folate deficiency alone was found to constitute 6 % of all 
cases and with vitamin B-12 deficiency they constituted 2 % of all cases[9].Folic 
acid is obtained primarily form plant foods and is essential for the synthesis and 
repair of DNA, as well as to act as a cofactor in a number of biological reactions. 
All of the functions of folic acid is performed by tetrahydrofolate( FH4) and other 
derivatives where the FH4 derivatives act as intermediates in transfer of one 
carbon units such as formyl and methyl groups to various compounds[16]in 
reactions such as (i) purine synthesis, (ii) conversion of homocysteine to 
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methionine (iii) deoxythymidylate synthesis,of which dTMP is perhaps the most 
important biologically since it is important for DNA synthesis. 
Sources of folate are plant foods like lettuce, spinach, asparagus and 
broccoli where it is in the form of folylpolyglutamates and get easily destroyed by 
cooking. The intestinal conjugases split the polyglutamates into monoglutamates 
that are readily absorbed into proximal jejunum where they are modified into 5- 
methyl tetrahydrofolate, the normal transport form of folate[16]. 
The causes for folate deficiency in elderly include . 
1. Decreased intake or malabsorption 
2. Hyperutilisation of folic acid by metabolic processes caused by 
malignancy, Crohn’s disease, rheumatoid arthritis 
3. Certain drugs that act as folic acid antagonists like methotrexate,(used for a 
variety of conditions in the elderly like rheumatoid arthritis, lupus, 
psoriasis, asthma ) phenytoin, trimethoprim, chemotherapeutic drugs 
damage DNA or inhibit DNA synthesis through several mechanisms and 
cause megaloblastic changes. 
4. The patients on dialysis for renal failure tend to lose folic acid in the 
dialysis fluid[13]. 
ANEMIA OF CHRONIC INFLAMMATION: 
It was formerly called anemia of chronic disease and it is a 
hypoproliferative anemia defined as having low serum iron and RBC levels 
despite normal levels iron stores occuring in the setting of chronic inflammation 
and is associated with decreased serum iron, decreased total iron binding capacity 
    12 
 
, increased serum ferritin levels and abundant stored iron in macrophages. The 
illnesses associated with this type of anemia include chronic microbial infections, 
chronic immune disorders and neoplasms. It is the most common cause of anemia 
in the elderly constituting 32 % of all etiologies according to NHANES III               
study [12]. 
Older adults tend to have higher levels of pro-inflammatory cytokines 
secondary to multiple co-morbid illnesses like atherosclerosis, diabetes mellitus 
and malignancies. The cytokines implicated in anemia of chronic inflammation 
include TNF α[21,22], IL 1 [23,24], IFN α[25], IL-6[24]. The pathophysiology implicated 
in anemia of chronic inflammation has a number of mechanisms, the most 
important of which is through hepcidin. Hepcidin as discussed earlier serves as a 
primary regulator of iron homeostasis. It serves to inhibit ferroportin which 
transports iron out of storage units. IL- 6 is found to increase hepcidin expression 
[26, 27], trapping iron within the macrophages and starving the erythroid precursors 
of the iron. In addition these progenitors do not proliferate adequately because 
erythropoietin levels are inappropriately low for the degree of anemia due to the 
action of IL-1, TNF α and TGFβ. TNF also inhibits the erythroid colony forming 
units thereby reducing erythropoeisis. Also cytokine IL-6 causes increased plasma 
volume thereby leading to a dilutional anemia. The erythrocyte survival is 
shortened in the setting of chronic inflammation which has been attributed to an 
extra corpuscular hemolysis. The cause for iron sequestration in setting of chronic 
inflammation is considered to be the body’s defense in fending off certain bacteria 
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dependant on iron for survival. The anemia is usually mild with either normocytic 
normochromic or microcytic hypochromic RBCs. 
RENAL INSUFFICIENCY: 
Chronic kidney disease is an important cause of anemia in elderly due to 
the fact that renal function declines with age[26,27] which is further decreased by 
diseases like diabetes mellitus and hypertension. Anemia in chronic renal disease 
is attributed mainly to decreased erythropoietin and reduced RBC survival. 
PATHOGENESIS: 
Role of Erythropoietin (EPO) 
It is a glycoprotein which is a hematopoietic growth factor which serves 
primarily to regulate RBC production. Secretion of EPO mainly occurs in the 
interstitial fibroblasts in the kidney in close association with peritubular capillary 
and proximal convoluted tubule with a lesser contribution from perisinusoidal 
cells in the liver[28]. Reduced tissue oxygenation potently induces a logarithmic 
increase in the EPO synthesis. EPO enhances erythrocyte production mainly by 
inhibiting apoptosis of erythroid progenitor cells and to a lesser degree by 
enhancing erythroid progenitor proliferation and differentiation. Serum 
erythropoietin levels have been shown to be inappropriately low at a creatinine 
clearance of < 40 %[29,30]. Mild decreases in hemoglobin may be detected at a 
creatinine clearance of 40- 60 ml/min[31,32]. Anemia is considered to be an 
indication of end stage kidney disease but women and diabetics may develop this 
complication at an earlier stage of the disease [33]. 
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Reduced red cell survival in kidney disease 
Some studies have shown that plasma from uremic patients can depress 
heme synthesis [34] or inhibit growth of erythroid colonies [35, 36]. Inhibitors of 
multipotential stem cell have also been found [37]. Secondary hyperparathyroidism 
in renal failure patients may also be a reason for marrow suppression [38]. Survival 
of RBC is found to be decreased and it has been discovered that the survival is 
related to the level of azotemia [39]. 
ANEMIA DUE TO ENDOCRINOPATHIES: 
1. Variations in thyroxine levels 
The prevalence of anemia in hypothyroid patients is 20 – 60 % [43]. Thyroid 
hormones are necessary for hemoglobin synthesis in adults and maturation of 
hemoglobin in the fetus [40, 41] hence hypothyroidism results in anemia[42]. The 
anemia in hypothyroidism is commonly normocytic[44] but occasionally 
macrocytic [45]. Both hypothyroidism and hyperthyroidism have been known to 
cause pernicious anemia[46]. 
2. Androgen deficiency 
Testosterone decreases with aging in men[47] and the greater rate of fall 
hemoglobin levels in men than in women suggests that falling testosterone maybe 
one of the causes of unexplained anemia. Testosterone accentuates proliferation of 
erythroid burst forming units and colony forming units by stimulating specific 
nuclear receptors and this effect is abolished by pretreatment of marrow cells with 
cyperoterone flutamide which block binding of androgens to their nuclear 
receptors [48]. The erythropoietic effects of testosterone is best explained by the 
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fact that following orchidectomy or androgen deprivation therapy for prostatic 
carcinoma hemoglobin levels fall by 1.2 g/dl to 1.5 g/dl on an average[49,50]. 
Hypopituitarism 
Anemia due to hypopituitarism is usually normocytic normochromic [51] 
and results chiefly from deficiency of hormones of the target organs controlled by 
the pituitary [51]. Panhypopituitarism produces effects on RBC production by 
decreasing oxygen consumption [52] which in turn decreases erythropoietin 
secretion and red cell mass until new equilibrium is established between oxygen 
supply and demand [51]. 
ANEMIA DUE TO MYELODYSPLASTIC SYNDROMES ( MDS ): 
Myelodysplastic syndromes represent a heterogeneous group of disorders 
characterized by clonal hematopoiesis and peripheral blood cytopenias resulting 
from bone marrow dysfunction [53]. Myelodysplasia is more common in elderly 
patients, more than 75 % of patients are over 60 years of age [53] with recent 
estimates of approximately 45000 new cases per year .Anemia in conjunction with 
macrocytosis, thrombocytosis or neutropenia in the absence of other causes 
should raise the suspicion of myelodysplasia[54,55]. The prevalence of anemia due 
to MDS has been estimated between 9 and 16 % based on three studies, NHANES 
III, Chicago and Stanford hospital and Clinics, VA Palo Alto Health Care system 
[9,63,64]. 
PATHOGENESIS: 
The basic pathophysiology in MDS involves increased apoptosis and 
proliferation. The proliferation is due to clonal expansion of a multipotent 
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hematopoietic progenitor that is capable of granulocyte, monocyte, erythrocyte 
and megakaryocyte differentiation[56, 57, 58, 59]. Also increased levels of apoptotic 
mediators are present including TNF – α , FAS antigen ( CD -95 ) and calcium 
dependant kinase [ 60, 61, 62 ]. The proliferation of progenitor cells results in a 
hypercellular marrow but failure to accumulate adequate number of mature cells 
results in cytopenia.The peripheral smear picture is that of macrocytosis or 
dimorphic RBC picture[65]. 
ANEMIA DUE TO PRIMARY HEMATOLOGIC DISORDERS: 
A variety of other primary hematologic disorders have anemia as a 
manifestation. Anemia in the elderly can be due to primary hematological 
malignancies like AML, CLL, aplastic anemia or Multiple myeloma. 
ACUTE MYELOGENEOUS LEUKEMIA 
In normal hematopoiesis, the myeloblast is an immature precursor of 
myeloid white blood cells; a normal myeloblast will gradually mature into a 
mature white blood cell. In AML, though, a single myeloblast accumulates 
genetic changes which "freeze" the cell in its immature state and prevent 
differentiation.[66]Such a mutation alone does not cause leukemia; however, when 
such a "differentiation arrest" is combined with other mutations which disrupt 
genes controlling proliferation, the result is the uncontrolled growth of an 
immature clone of cells, leading to the clinical entity of AML.[67]. Anemia due to 
AML result from the growth of leukemic clone cells, which tends to displace or 
interfere with the development of normal blood cells in the bone marrow[68]. 
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CHRONIC LYMPHOID LEUKEMIA 
Chronic lymphoid leukemia (CLL), is the most common type of leukemia 
in adults[69] affecting 2 to 6 individuals per 100000 per year. It is a neoplastic 
disease characterized by the accumulation of small mature-appearing CD5+ B 
lymphocytes in the blood, marrow, and lymphoid tissues. The causes of this 
disease are unknown, although genetic factors likely contribute to its 
development. Anemia develops due to crowding of bone marrow with 
proliferating lymphocytes thus decreasing erythroid precursors. 
MULTIPLE MYELOMA 
Multiple myeloma (MM) is a malignant plasma cell disorder that accounts 
for approximately 10% of all hematologic cancers[70]. The disease is characterized 
by monoclonal proliferation of plasma cells together with overproduction of a 
monoclonal antibody,[71] often accompanied by anemia, hypercalcemia, renal 
insufficiency, or bone lesions[72]. Approximately 97% of MM patients develop 
anemia during the course of their illness, and 70% are anemic at diagnosis. The 
anemia is usually normocytic normochromic,[73] serum-iron levels are normal to 
low, serum ferritin is high, and hemosiderin is prominent in bone marrow 
macrophages.[74] This suggests than iron release from reticulo endothelial 
macrophages is impaired, consistent with anemia of inflammation[75]. 
APLASTIC ANEMIA 
It is a hypoproliferative state which can occur due to several causes some 
of which are toxins like benzene, drugs like antimetabolites, anthracyclines, 
autoimmune diseases and inherited causes like Fanconi’s anemia and Diamond 
    18 
 
Schwachman syndrome[79,80,81].According to the International Aplastic Anemia 
and Agranulocytosis Study the overall incidence of aplastic anemia is 2 cases/ I 
million with a higher incidence in southeast asia[76]. It commonly presents in the 
2nd decade with a smaller peak in incidence after the age of 60 years [77, 78]. 
Immune injury to the marrow after drug-, viral-, or toxin-induced marrow aplasia 
could result from induction of neoantigens that provoke a secondary T cell–
mediated attack on hematopoietic cells [82] causing reduced hematopoietic 
precursors leading to the pancytopenia. 
ANEMIA SECONDARY TO BONE MARROW INFILTRATES – 
MYELOPHTHISIC ANEMIA: 
This is a type of anemia that results from marrow infiltration by tumour 
cells or non hematopoietic tissue. The marrow environment is susceptible to 
infiltration by almost all cancers but the most common are lung, breast and 
prostate cancers [83]. The anemia is usually mild to moderate and peripheral smear 
may show presence of tear drop RBCs and nucleated RBCs a feature suggestive 
of marrow infiltration. Bone marrow biopsy is the most reliable procedure to 
confirm the diagnosis and should performed in all patients suspected of having 
myelophthisic anemia [83, 84, 85]. 
ANEMIA DUE TO HEMOLYTIC DISEASE: 
Hemolytic anemias are the result of RBC deficiency due to premature 
destruction of RBC either within blood vessels ( intravascular) or elsewhere 
(extravascular) resulting in shortened RBC lifespan and the marrow is unable to 
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compensate for the loss resulting in anemia .They can be classified as inherited 
and acquired. Inherited causes for hemolysis include, 
INTRINSIC MEMBRANE DEFECT: 
1. Hereditary spherocytosis, hereditary elliptocytosis,: 
In hereditary spherocytosis there is defect in proteins of erythrocyte 
membrane including ankyrin, band 3, β spectrin, α- spectrin and protein 4.2. This 
leads to increased membrane fragility leading to loss of membrane surface area 
relative to intracellular volume, accounting for the spheroidal shape and decreased 
deformability of red cell[86]. The size of fenestrations in the venous sinuses in the 
spleen is small relative to the RBC size, and to pass through requires significant 
deformability of the red cell and its membrane. This, however, is a major problem 
for spherocytes, which have lost surface area and are dehydrated and get lysed as 
they pass through. It presents with chronically compensated mild to moderate 
hemolytic anemia and its diagnosis is based on presence of spherocytes in 
peripheral smear, a positive family history and a negative direct antiglobin test. 
The mean corpuscular hemoglobin concentration is frequently elevated [87]. 
Hereditary elliptocytosis (HE) and variants 
Similar to HS, these group of disorders occur due to defects in RBC 
membrane proteins of which spectrin defect is commonest. The mutation impairs 
ability of spectrin dimers to self associate into dimers and tetramers thereby 
disrupting the membrane cytoskeleton and reducing the deformability of RBC s as 
they pass through splenic sinusoids. 
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Hereditary pyropoikilocytosis is a variant of HE and a severe congenital 
hemolytic anemia that presents with RBC fragments, poikilocytes and 
microspherocytes on peripheral smear. 
2.Hemolysis due to abnormal hemoglobins 
This can be due to either reduced synthesis of globin chains ( quantitative) 
or defective synthesis of globin chains( qualitative). 
QUANTITATIVE DEFECTS 
Thalassemia 
This is a group of congenital anemia in which there is deficient synthesis of 
one or more globin subunits of normal hemoglobin. There is either production of 
either α or β (called α thalassemia or β thalassemia respectively) chains as a result 
of which there is accumulation of free globin chains that cause lysis of RBC 
precursors. It can occur in three forms thalassemia major in which there is severe 
anemia requiring frequent transfusions, thalassemia minor or thalassemia 
intermedia in both cases there is mild to moderate anemia. The prevalence of 
anemia due to thalassemia in elderly ranges from 12 – 20 %[9, 63, 64]. 
QUALITATIVE DEFECTS 
Sickle Cell Anemia 
Sickle hemoglobin is a mutant hemoglobin in which valine has been 
substituted for the glutamic acid normally at the sixth amino acid of the β- globin 
chain. This hemoglobin becomes polymerized and becomes poorly soluble when 
the oxygen tension is lowered and red cells that contain this hemoglobin become 
distorted and rigid. Hemolysis in sickle cell anemia results from the lysis of 
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complement-sensitive red cells [88] and Hb lost during sickling or shear-induced 
membrane fragmentation[89]. Extravascular hemolysis may occur by two 
mechanisms: monocyte and macrophage recognition and phagocytosis of red cells 
that have undergone sickling- or oxidation-induced membrane[90] and physical 
entrapment of rheologically compromised red cells[91] Sickling and oxidation-
induced membrane changes promote cell dehydration and clustering of membrane 
protein band 3 which leads to accumulation of IgG and complement on the sickle 
cell surface [92]. 
3. Erythrocyte enzymopathies: 
Glucose-6-phosphate dehydrogenase (G6PD) is a highly conserved 
housekeeping enzyme and rate-limiting enzyme of the pentose phosphate pathway 
in all cells[93].The pentose phosphate pathway (PPP) converts glucose to ribose-5-
phosphate, a precursor to RNA, DNA, ATP, CoA, NAD, and FAD and also 
provides reductive potential in the form of NADPH[94]. G6PD is a ubiquitous 
enzyme that must be quite ancient in evolution because it has been found in all 
organisms, from prokaryotes to yeasts, to protozoa, to plants, and animals [95,96]. 
G6PD deficiency results from mutations[97]  in the G6PD gene and is well-known 
common cause of hemolytic anemia in human. RBCs lack other pathways to 
generate NADPH so G6PD deficiency becomes especially lethal in red blood 
cells, where any oxidative stress will result in hemolytic anemia. 
Acquired Causes Of Hemolytic Anemia 
Acquired causes of hemolysis include 
1. Hemolysis due to mechanical injury to RBCs 
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2. Immune mediated injury to RBCs 
3. Drug induced injury to RBCs 
4. Hemolysis due to infections 
Mechanical injury to RBCs can occur due to several causes 
(i) Cardiac hemolysis 
(ii) Microangiopathic haemolytic anemia 
Cardiac hemolysis 
This is due to injury to the red blood cells owing to turbulence in the heart 
chamber because of the pressure gradient created most commonly by prosthetic 
valves. It can also be caused due to aortic stenosis, mitral valve disease, 
coarctation of aorta. 
Microangiopathic hemolytic anemia   (MAHA) 
This encompasses several etiologies, the common mechanism in these 
disorders is a microvascular lesion that results in luminal narrowing often due to 
deposition of fibrin and platelets. The causes of MAHA are 
a. Thrombotic thrombocytopenic purpura ( TTP) 
b. Disseminated malignancies 
TTP: 
In this disease there is deficiency of the enzyme ADAMTS13 also 
designated as Von Willebrand Factor metalloprotease whose function of 
ADAMTS13 is to degrade the high molecular weight multimers of Von 
Willebrand Factor (vWF). In its absence the vWf multimers accumulate in plasma 
and promote platelet activation and aggregation. The deficiency can be either 
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acquired or inherited where in the acquired form there is antibody against the 
ADAMTS13 and in the inherited form there is deficiency of ADAMTS13. 
DISSEMINATED MALIGNANCIES 
Hemolysis due to disseminated malignancies is common in pancreatic, 
lung and prostatic carcinomas [101, 102]. Hemolysis can occur either due to DIC or 
intravascular tumour emboli. In case of DIC, a protease found in mucin secreted 
by adenocarcinoma directly activates factor X. Subsequently the coagulation 
cascade gets activated resulting in deposition of fibrin, formation of intravascular 
hyaline thrombi which cause shearing of red cells. Intravascular tumor emboli 
disrupt the endothelium, promoting deposition of fibrin, adherence of platelets, 
intimal hyperplasia, and vascular hypertrophy[98,99,100].Peripheral smear shows 
presence of moderate to severe anemia, schistocytes, helmet cells, 
microspherocytes, polychromasia and nRBCs[100], normal to high WBC count 
with a left shifted differential count[99, 100, 103]. Marrow aspiration and biopsy 
reveal erythroidhyperplasia , normal to high numbers of megakaryocytes and 
tumour invasion in 55 % of patients[103]. 
IMMUNE MEDIATED HEMOLYSIS 
It is characterized by shortened RBC lifespan and presence of antibodies 
directed against the red cells. The antibodies can either be warm antibody type or 
cold antibody type. 
Warm antibody type: 
This type is predominantly due to IgG type immunoglobulin which acts 
best at a temperature of 370 C with or without complement proteins. The 
    24 
 
autoantibody coated RBCs are trapped by macrophages in Billroth cords of spleen 
to a lesser extent by Kupffer cells in liver. 
Cold antibody type: 
It is caused by IgM antibodies that bind red cells at low temperatures (00C 
– 40C). The IgM antibodies bind to red cells causing agglutination and rapid 
complement fixation. This deposits sublytic quantities of C3b which leads to 
removal of affected red cells. 
DRUG MEDIATED HEMOLYSIS: 
Injury to RBCs due to drugs can occur due to several mechanisms: 
(i) Drug adsorption mechanism: 
Drugs like penicillin binds firmly to proteins on RBC membrane which is 
recognized by IgG antibodies and these RBCs are sequestered in the spleen. 
(i) Ternary complex mechanism 
In drugs like quinidine the antibodies recognize a complex of the drug and 
a membrane protein, fix complement and cause intravascular hemolysis. They can 
also act as opsonins and cause  extravascular hemolysis. 
(i) Autoantibody mechanism 
Drugs like α-methyl dopa induce autoantibody in an unknown manner, 
particularly Rh blood group antigens. 
HEMOLYTIC ANEMIA DUE TO INFECTIONS 
Several organisms can cause hemolysis by different mechanisms. Some 
like Plasmodium and Babesia colonize RBCs and cause hemolysis and yet others 
like Bartonella, Clostridium adhere to cell surface and such cells are removed by 
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the spleen. Other mechanisms involved maybe the action of antibodies against 
antigen coated cells leading to agglutination [104] or to complement mediated 
lysis[105] . 
UNEXPLAINED ANEMIA 
The traditional notion that anemia in geriatric patients signifies some 
serious underlying disorder is not always true. A proportion of elderly have 
anemia that does not meet any criteria for any etiology. Even with the advent of 
better tests, such as serum ferritin , methylmalonic acid, and soluble transferrin 
receptor, a significant portion of elderly persons with anemia will be diagnosed as 
having unexplained anemia[106].The pathophysiology of unexplained anemia is 
poorly understood and is primarily a diagnosis of exclusion. Whether unexplained 
anemia represents a spectrum of undiagnosed diseases is unclear. Several theories 
have been postulated to explain this phenomenon, including decreased production 
of hematologic factors, inflammatory cytokine presence, marrow abnormalities 
and androgen deficiencies[107]. 
CONSEQUENCES OF ANEMIA IN GERIATRIC PATIENTS: 
Morbidity and mortality related to anemia in the geriatric age group can 
occur from underlying disease or due to effects of the anemia itself and has the 
following consequences: 
MUSCLE AND BONE 
Anemia and osteoporosis are both prevalent in the geriatric population with 
a negative relationship between low hemoglobin levels and bone mass. Also lower 
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hemoglobin levels are associated with lower ankle extension strength, lower 
muscle density and less muscle mass. 
MOBILITY 
Anemia has been associated with greater average decline in physical 
performance[108,109,110].The risk of mobility problems in persons with hemoglobin< 
12 mg/dl is more than twice than that occurring  in persons with hemoglobin > 13 
mg/dl. 
FALLS 
Thirty percent of people over the age of 65 years fall at least once a year. 
Falls and fractures are significant causes of disability, admission to institutional 
care and mortality. Hemoglobin level less than 10g/dl is associated with a higher 
incidence of fall and injury to hip and head as compared to those who were not 
anemic[110, 111, 112]. 
COGNITION 
Anemia due to vitamin B 12 deficiency and anemia alone has been 
demonstrated to be a risk factor for functional and cognitive decline[113]. 
CARDIAC DISEASE 
Acute and chronic anemia can cause congestive cardiac failure in patients 
without heart disease and may precipitate congestive heart failure and angina in 
patients with underlying heart disease[114]. 
HOSPITAL ADMISSIONS 
Anemia in elderly has been associated with frequent hospital admission for 
various causes[115]. 
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HISTORY AND PHYSICAL EXAMINATION: 
MEDICAL HISTORY: 
Recent hospitalization can cause anemia in the elderly as a result of 
multiple phlebotomies as well as the acute illness itself [116, 117]. Any history of 
recent surgery leads one to think of acute blood loss, also when the person needs 
transfusion during surgery it implicates the person was anemic before the surgery 
and the presence of another condition preventing an appropriate response to blood 
loss should be thought of. Diseases that cause anemia including malignancies, 
myelodysplastic syndrome, chronic kidney disease and rheumatologic diseases 
should be taken into account. Dietary history is important since strict vegan diets 
can raise the risk of B-12 deficiency [118] and history of alcoholism should not be 
overlooked as it is a cause of B 12 and folate deficiencies[118]. 
History of previous transfusions is an indication of the presence of a 
chronic illness like thalassemia or other hemolytic diseases. 
History of drug intake should be reviewed to rule out the drugs as a cause 
for anemia. 
SYMPTOMS: 
Most symptoms of anemia are non specific; however a temporal relation 
between falling hemoglobin and exacerbation of symptoms is very useful. 
General symptoms include the following: 
• Fatigue 
• Weakness 
• Exertional dyspnoea 
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• Tinnitus 
• Presyncope 
• Palpitations 
• Poor concentration 
Symptoms of iron deficiency: 
• Blood loss- tarry stools, hematochezia, hematuria 
• Pica 
• Dysphagia 
• Mouth and tongue soreness 
Symptoms of vitamin B 12 deficiency 
• Neuropathy 
• Ataxia 
• Dementia 
Symptoms of hemolysis 
• Jaundice 
• Dark coloured of urine 
PHYSICAL EXAMINATION: 
Careful physical examination helps in revealing cause of the anemia hence 
justifying comprehensive physical examination. One should look for the 
following: 
• Pallor ( present in anemia due to any cause)( image 1) 
• Icterus ( seen in haemolytic anemia) (image 2) 
• Koilonychia ( in iron deficiency) (image 3) 
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• Lymphadenopathy ( in metastasis due to malignancies) (image 4) 
• Glossitis (image 5) 
• Aphthous ulcers (image 6) 
• Angular stomatis (image 7) 
• Pedal edema (image 8) 
• Tachycardia ( in severe anaemia due to any cause) 
• Cardiac murmurs ( in severe anemia ) 
• Hepatomegaly (in haemolytic anemias) 
• Splenomegaly ( in haemolytic anemia ) 
LABORATORY ASSESSMENT OF ANEMIA: 
After obtaining history and initial physical examination laboratory 
evaluation should be done which includes: 
• Complete blood count 
• Stool for occult blood 
• Iron profile 
• Vitamin profile 
• Erythropoietin level 
• Peripheral smear examination 
COMPLETE BLOOD COUNT: 
The CBC is important for the diagnosis of anemia and for monitoring 
disease progression and treatment efficacy. When assessing the elderly anemia 
patient, the most important components of the CBC are [119]: 
 
  
IMAGE 1. BULBAR CONJUNCTIVAL PALLOR 
 
 
 
IMAGE 2. ICTERUS 
 
 
 
  
IMAGE 3. KOILONYCHIA 
 
 
IMAGE 4. LYMPHADENOPATHY 
 IMAGE 5. GLOSSITIS 
 
 
IMAGE 6. APTHOUS ULCERS 
 
  
IMAGE 7. ANGULAR STOMATITIS 
 
 
IMAGE 8 PEDAL EDEMA 
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Erythrocyte (RBC) count:  
Reports  the total number of RBCs per litre of whole blood. 
• Normal range for men: 4.7–6.1 million cells/mcL 
• Normal range for women: 4.2–5.4 million cells/mcL 
Hemoglobin (HgB): 
 Measures the amount of hemoglobin present in the blood 
• Normal range for men: 13–17 g/dL 
• Normal range for women: 12–16 g/dL 
Hematocrit (HCT): 
Packed  cell volume in proportion to blood volume. 
• Normal range for men: 40% to 52% 
• Normal range for women: 36% to 48% 
Mean cell (corpuscular) volume (MCV): 
It measures the average size of RBCs, a diagnostic parameter for evaluating 
anemia, and differentiates microcytic and normocytic anemia in the elderly. 
• Normal range: 81–100 fL 
• Macrocytosis: Greater than 100 fL with large RBCs 
• Microcytosis: Less than 81 fL with small RBCs 
Mean cell hemoglobin (MCH):  
It is the average amount of Hb in a  RBC. 
• Normal range: 27–34 Hb/cell 
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Mean cell hemoglobin concentration (MCHC): 
It is the average concentration of Hgb in an RBC. 
• Normal range: 30% to 36% 
RBC distribution width (RDW-CV): 
It measures  variations in the size of RBCs. 
• Normal range: 12% to 14% 
Leukocyte (white blood cell) count: 
Reports the number of leukocytes in the blood; the differential includes different 
types of leukocytes (i.e., neutrophil, eosinophil, basophil, lymphocyte, monocyte). 
• Normal range: 4,500–10,000 cells/ mcL 
Thrombocytes /platelet count: 
It indicates the number of platelets present. 
• Normal range: 150,000–450,000 cells/ mcL 
STOOL EXAMINATION: 
Stool specimen for occult blood is another essential test in evaluating 
anemia in elderly as GI bleed is often a major etiologic factor. The bleed may be 
intermittent so three stool samples testing is recommended. Before the test, the 
patient is advised to stop iron supplements if any, to avoid red meat and food with 
red dye for 3 days before the test. 
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ENDOSCOPIC EVALUATION: 
If the patient tests positive for occult blood in the stool sample a 
gastroenterology consult is ideal. The patient will need endoscopy or colonoscopy 
to identify the bleed. It might indicate haemorrhoids or less other serious 
problems, it might also indicate malignancy. 
IRON PROFILE: 
Serum iron is not an adequate test to exclude iron deficiency. Numerous 
tests are available to diagnose iron deficiency including RBC, MCV, serum iron, 
serum transferrin, iron saturation, serum ferritin, soluble transferrin receptor 
(sTFR). 
Serum ferritin is the most useful test for diagnosing iron deficiency. Low 
serum ferritin is highly specific for iron deficiency [120].As an acute phase reactant, 
ferritin can be elevated in inflammation, complicating the diagnosis of iron 
deficiency anemia in the presence of inflammation[121].Values between 18 and 44 
ng/ml are highly suggestive of iron deficiency in the elderly[122, 123]. 
Alternative strategies to diagnose iron deficiency anemia have been 
studied, most commonly employing the sTFR. The sTFR is a truncated fragment 
of the membrane receptor that is increased in iron deficiency, when iron 
availability for erythropoiesis is low. STFR enhances diagnostic sensitivity in 
elderly persons compared with using a very low serum ferritin for iron deficiency 
anemia[124]. Another method standardizes sTFR based on the serum ferritin. By 
using the log of the sTFR/ferritin, a ratio greater than 2.5 may indicate iron 
deficiency. However, raising the threshold of ferritin to less than 30-50 ng/mL 
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affords a similar or better diagnostic performance.[123, 125] Further, sTFR is less 
sensitive in detecting early iron deficiency compared with ferritin.[126]  
The iron profile will measure: 
Total serum iron 
• Normal range for men: 60–176 mcg/dL 
• Normal range for women: 45–170 mcg/dL 
Total iron binding capacity 
• Normal range: 250–450 mcg/dL 
Unsaturated iron binding capacity 
• Normal range: 100–400 mcg/dL 
Transferrin saturation 
• Normal range: 20% to 50% 
Serum ferritin 
• Normal range for men: 12–350 ng/mL 
• Normal range for women: 12–200 ng/mL 
VITAMIN PROFILE: 
The vitamin profile may include measurements of: 
Folate (vitamin B9) 
• Normal range: 4–20 mcM 
Vitamin B12 (cobalamin) 
• Normal range: 200–900 pg/mL 
Methylmalonic acid 
• Normal range: 73–271 nM 
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Homocysteine 
• Normal range: 5.1–13.9 mcM 
Vitamin B 12 and folate deficiencies though rare are essential to rule out as a 
cause of anemia as these are reversible causes. Low vitamin B-12 levels are 
frequent in older adults. If a level less than 200 pg/mL is detected, then cause of 
vitamin B-12 deficiency (eg, pernicious anemia, malabsorption) should be 
investigated and vitamin B-12 replenished. For equivocal levels of vitamin B-12, 
such as a level between 200 and 350 pg/mL, evaluate methylmalonic acid. An 
elevated methylmalonic acid level is evidence of a vitamin B-12 tissue deficiency. 
One must recognize that methylmalonic acid is also elevated in renal dysfunction. 
Homocysteine is elevated in vitamin B-12 deficiency and folate deficiency. If the 
methylmalonic acid is elevated in the setting of anemia and a low vitamin B-12, 
evaluate for vitamin B-12 deficiency and empirically treat the patient. 
ERYTHROPOIETIN LEVELS: 
Erythropoietin level is not ordered frequently, but it is used in patients with 
unexplained polycythemia which is a condition with abnormally elevated 
concentration of RBCs. The erythropoietin level is also reduced in chronic kidney 
disease and myelodysplasia. The normal range is 4.5–21.3 mU/mL[127]. Measuring 
serum erythropoietin levels is of little diagnostic utility in patients with chronic 
kidney disease. 
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PERIPHERAL SMEAR EXAMINATION: 
Peripheral blood smear is essential to determine the caue of anemia. The 
peripheral enables one to study the morphology of the three cell components and 
is highly subjective but highly rewarding. 
MORPHOLOGY OF RED BLOOD CELLS 
In a well spread dried and stained blood film the RBC have round smooth 
contours and diameters between 6.0 – 8.5 µm[128] with a central pallor 
approximately one third of the area of the red blood cell. 
Anisocytosis and poikilocytosis 
These terms mean more variation in size (anisocytosis) or shape 
(poikilocytosis) (image 9) than that usually expected in a smear. It is seen in iron 
deficiency anemia, megaloblastic anemia, thalassemias and myelodysplastic 
syndromes. 
Macrocytes 
Macrocytes are present classically in megaloblastic anemias[128] and also in 
aplastic anemia, myelodysplastic syndromes and dyserythropoietic conditions. 
Microcytes 
Microcytes in a peripheral smear (image 10) occur in defects of 
hemoglobin synthesis[128] and are seen in iron deficiency, thalassemia, severe 
cases of anemia of chronic disease.  
 
 
 
  
IMAGE 9. Photomicrograph showing peripheral smear with 
Anisopoikilocytosis (1000x, oil, leishman stain) 
 
 
IMAGE 10. Photomicrograph showing peripheral smear with  Microcytic 
Red Blood Corpuscles  (1000x, oil, leishman stain) 
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Basophilic stippling 
The presence of basophilic granules that are distributed throughout the cell 
is termed basophilic stippling and is seen in conditions like thalassemia, liver 
disease, lead poisoning and megaloblastic anemias. 
Hypochromia 
Occurrence of the central pallor more than one third of the area of the cell 
helps one to identify hypochromia which occurs in conditions of reduced 
hemoglobin synthesis or unusually red cells. Iron deficiency anemia and 
sideroblasticanemias are some of causes of hypochromia. 
Hyperchromasia 
Unusually deep staining of cells with loss of central pallor is seen when 
theres presence of macrocytes and when are rounded[128]. It is seen in 
megaloblastic anemias and spherocytosis. 
Schistocytosis 
Schistocytes are red cell fragments that are smaller than normal red cells 
with irregular or round contour (image 11) and with hypochromasia or 
hyperchromasia. It can occur in conditions like thalassemias, congenital 
dyserythropoietic anemia, microangiopathic hemolytic anemia, cardiac hemolytic 
anemia and in thermal injury like burns. 
Acanthocytosis 
This describes red cells with irregular spicules  of varying length, thickness 
and irregularly distributed over the cell surface and seen in abnormal phospholipid 
metabolism[129] and in liver diseases[130] 
  
 
 
 
 
IMAGE 11. Photomicrograph showing peripheral smear with Schistocytes 
(1000x, oil, leishman stain) 
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Target cells 
This term refers to cells with centrally stained area and a peripheral rim of 
hemoglobinized cytoplasm separated by non stained or lightly staining cytoplasm 
and is present in thalassemias, hereditary hypolipoproteinemia and some cases of 
iron deficiency anemia. 
Sickle cells 
Sickle cells are present in freshly drawn samples of blood from individuals 
homozygous for hemoglobin S and can be observed when subjected to hypoxia. 
Howell-jolly bodies 
Howell-jolly bodies are round cytoplasmic inclusions that stain purple with 
Romanowsky stains and are regularly present following splenectomy[128] 
MORPHOLOGY OF LEUCOCYTES 
Neutrophils 
Normal neutrophils are 13µm in size with segmented nucleus having 2- 5 
lobes connected by tapering chromatin strands and cytoplasm shows fine 
azurophilic granules when stained with Romanowsky stains. The nuclear 
chromatin is peripherally condensed with clumping. 
Lymphocytes 
The circulating lymphocytes are uniform in size about 9 µm in diameter 
with a thin rim of cytoplasm occasionally showing scant azurophilic granules. 
Eosinophils 
They are of size 12- 17 µm  with a bilobed nucleus usually and have bright 
orange granules in the cytoplasm. 
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Monocytes 
Monocytes are the largest of circulating leucocytes of size 15- 18 µm with 
blue- grey cytoplasm having variable number of reddish granules and large curved 
nucleus that maybe folded or curved. 
Basophils 
They are the least number of leucocytes with variably sized dark blue 
granules in the cytoplasm that tend to obscure the segmented nucleus. 
BONE MARROW STUDY 
The absolute indications for bone marrow examination include evaluation 
of leucopenia, anemia, pancytopenia, leucoerythroblastosis and diagnosis of 
leukemia as well as monitoring the effects of therapy[131,132]. Relative indications 
include evaluation of iron metabolism unexplained fever (PUO) or splenomegaly, 
and sampling for chromosomal analysis, immunophenotyping, or microbiological 
cultures[131, 132]. 
Iron deficiency anemia 
The bone marrow in iron deficiency is characterized by mild to moderate 
erythroid hyperplasia with striking nuclear distortions, resembling those found in 
dyserythropoietic anemias[133]. Karyorrhexis and nuclear budding are particularly 
common, but multinuclearity, nuclear fragmentation, and even intranuclear 
bridging may be observed. The individual normoblasts appear small and may have 
scanty cytoplasm, often with irregular, ragged borders. Macrophage iron is absent 
or severely reduced in the marrow, spleen, and liver of iron-deficient subjects. 
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Megaloblastic anemia 
Aspirated marrow is cellular with striking megaloblastic changes, 
especially in the erythroid series. The high apoptosis rate of erythroid precursor 
cells in the marrow creates more globin lysis and, thus, jaundice. Sideroblasts are 
increased in number and contain increased numbers of iron granules. The ratio of 
myeloid to erythroid precursors falls to 1:1 or lower, and granulocyte reserves 
may be decreased. 
Hemolytic anemia 
The marrow shows hyperplasia of the erythroid series with normoblasts 
constituting 25 -60 % of all nucleated cells. 
Anemia of chronic inflammation 
The marrow in cases of anemia with chronic inflammation is moderately 
cellular with erythroid hyperplasia and normal erythroid maturation. 
Myelodysplastic syndrome 
Marrow in myelodysplastic syndromes may be either normocellular or 
hypercellular [134,135,136]. The erythroid series may show large or small 
erythroblasts, nuclear fragmentation and stippled erythroblasts[134, 135, 136]. 
Granulocytic precursors show hypogranulation, monocytoid appearing 
granulocytes and Pelger-Huet anomaly of the neutrophils. Megakaryocytes appear 
micro megakaryocytes with unilobed or bilobed nuclei[134, 135, 136] 
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Myelophthisic anemia 
Marrow aspirate is usually unyielding and marrow biopsy reveals clusters 
of large anaplastic cancer cells bearing features of the primary tumour and 
lymphocytes in cases of lymphoproliferative disorders can be present 
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MATERIALS AND METHODS 
 
STUDY LOCATION 
Departments of General medicine, General surgery and Pathology, 
Tirunelveli Medical College Hospital, Tirunelveli – 11. 
PERIOD OF STUDY 
2 years between September 2013 and September  2015 
SIZE OF SAMPLE 
100 geriatric patients (> 65 YEARS OLD) with clinical features of anemia. 
TYPE OF STUDY 
Hospital based observational study 
INCLUSION CRITERIA 
1. Patients above the age of 65 years 
2. Men with hemoglobin levels less than 13 mg/dL and women with 
hemoglobin less than 12 mg/dL 
EXCLUSION CRITERIA 
1. Patients below age of 65 years 
2. Patients who refused to consent to take part in the study 
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3.  Patients who refused to consent for venipuncture for collection of 
blood samples. 
METHODOLOGY 
The cases received in the hematology department for peripheral smear 
reporting were screened and 100 cases that showed hemoglobin levels lower than 
standard WHO values were chosen. The entire medical history was obtained from 
each of the cases including previous medical reports and imaging studies. Blood 
samples were collected from all patients in plain vacutainers and EDTA 
containing vacutainers. Complete blood counts for all the samples was done using 
SYSMEX 3 part differential analyzer and the  RBC indices was noted along with 
total WBC count, differential count, platelet count and hematocrit.ESR for all 
cases was done using Westergren tube. Peripheral smears were made for all the 
samples and stained using Leishman stain. Supravital staining using methylene 
blue was done for reticulocyte counting. Ferritin, iron and TIBC for all samples 
was done using  SPINREACT kits for all the three by the following methods. 
FERRITIN 
The patients’ blood was collected in plain vacutainers and serum separated 
by centrifuging at 3000 rpm / min for 5 minutes. The tubes that were used to run 
the ferritin assay were prewarmed to 37• C before running the test. 400 µL of the 
R1 buffer ( provided with the kit ) was added to the prewarmed tube followed by 
100 µL of R2 latex buffer ( provided with the kit ), then 50 µL of the patient’s 
serum was added. The result is then read using turbidometry at an absorbance of 
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540 nm. The values were standardized using control sera and fixed between 30 
and 220 µg/ L for men and between 20 and 110 µg/L for women   
IRON 
The assay for iron was run using a blank for every sample. The pair of 
tubes were prewarmed to 37• C to which was added 500µL of R1 solution  ( 
working solution to which R2 was already mixed ), 100 µL patient’s serum, 100 
µL distilled water were added. To the test tube 25 µL R3 was added whereas in 
the blank this step was avoided.  The tubes were then incubated at room 
temperature for 10 minutes and the results were obtained using colorimetry at an 
absorbance of 570 nm. The test was standardized using control sera and normal 
range was set between 65 and 175 µg/L for men and between 40 and 150 µg/L for 
women 
TOTAL IRON BINDING CAPACITY 
To prewarmed test tube 250 µL of patient serum was added followed by 
500 µL of R5 solution. The mixture was incubated at room temperature for 10 
minutes after which 1 ½ spoonfuls of R6 reagent was added. This mixture was 
centrifuged at 3000 rpm for 15 minutes following 10 minutes incubation and the 
supernatant was collected and iron measured using previously said method. The 
standard value was set between 200 and 400 µg/dL for both men and women.  
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RESULTS AND OBSERVATIONS 
 
AGE DISTRIBUTION 
Of the 100 patients studied 87 patients [ 87 %] fall in the age group of 65 
to 75 years, 11 patients [11%]fall  in the age group 0f 76 – 85 years and 2 patients 
fall in the age group of  86-95 years. 
 
TABLE NO.2.  AGE DISTRIBUTION 
AGE NO.OF PATIENTS PERCENTAGE 
65-75yrs 87 87 
76-85yrs 11 11 
86-95yrs 2 2 
 
FIGURE NO.2. AGE DISTRIBUTION 
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ETIOLOGY OF ANEMIA  
Among the causes for anemia iron deficiency was the commonest 
constituting 43% of the cases followed by anemia of chronic diseases which 
constituted 32 % of the cases. Among the causes for anemia due to chronic 
inflammation 4 patients had both diabetes and hypertension, 2 had pulmonary 
tuberculosis, 2 had coronary heart disease, 1 was a case of thymoma, 2 were 
hematological malignancies, 2 cases were malignant melanomas, 4 were lung 
cancers, 3 breast cancers, 3 GI malignancies, 1 was a bone tumour, and 2 were 
unidentified malignancies. The next common cause for anemia was anemia of 
chronic kidney disease (11%) followed by anemia of unknown etiology (10%). 
TABLE NO.  5. ETIOLOGY OF ANEMIA 
 
 
 
 
 
DIAGNOSIS NO.OF 
CASES 
PERCENTAGE
IRON DEFICIENCY 43 43 
ANEMIA OF CHRONIC DISEASE 32 32 
CHRONIC KIDNEY DISEASE 11 11 
B 12 OR FOLATE DEFICIENCY  1 1 
UNEXPLAINED 11 11 
OTHERS 1 1 
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TABLE NO. 7. CLINICAL FEATURES OF ANEMIA 
Easy fatiguability 75% 
GI bleed 10% 
Abdominal distention 20% 
Chronic drug intake 42% 
Falls 8% 
Smoking 28% 
Alcoholism 30% 
Diabetes 35% 
Hypertension 30% 
Features of renal disease 10% 
Thyroid symptoms 3% 
Known malignancies 7% 
palpitation 9% 
Pallor 92% 
Clubbing 15% 
Icterus 4% 
Pedal edema 21% 
Koilonychia 7% 
Glossitis 11% 
Aphthous ulcer 7% 
Lymphadenopathy 2% 
Hepatomegaly 5% 
Splenomegaly 6% 
Tachycardia 15% 
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TABLE NO. 8. CLINICAL PROFILE OF PATIENTS WITH  
MILD ANEMIA 
Easy fatiguability 16% 
GI bleed 0% 
Abdominal distention 3% 
Chronic drug intake 12% 
Falls 0% 
Diabetic only 3% 
Both diabetic and hypertensive 10% 
Signs of renal failure 2% 
Signs of thyroid disturbances 1% 
malignancies 6% 
palpitations 3% 
Pallor  27% 
clubbing 5% 
icterus 0% 
Pedal edema 4% 
koilonychia 3% 
Glossitis  0% 
Aphthous ulcer 1% 
Lymphadenopathy 6% 
hepatomegaly 0% 
Splenomegaly 2% 
tachycardia 2% 
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TABLE NO. 9. CLINICAL PROFILE OF PATIENTS WITH  
MODERATE ANEMIA 
Easy fatiguability 18% 
GI bleed 3% 
Abdominal distention 7% 
Chronic drug intake 12% 
Falls 1% 
Diabetic only 2% 
Both diabetic and hypertensive 9% 
Signs of renal failure 6% 
Signs of thyroid disturbances 1% 
malignancies 3% 
palpitations 1% 
Pallor  39% 
clubbing 4% 
icterus 2% 
Pedal edema 7% 
koilonychia 2% 
Glossitis  7% 
Aphthous ulcer 4% 
Lymphadenopathy 0% 
hepatomegaly 3% 
Splenomegaly 3% 
tachycardia 2% 
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TABLE NO.10. CLINICAL PROFILE OF PATIENTS WITH  
SEVERE ANEMIA 
Easy fatiguability 29% 
GI bleed 4% 
Abdominal distention 7% 
Chronic drug intake 14% 
Falls 5% 
Diabetic only 7% 
Both diabetic and hypertensive 9% 
Signs of renal failure 2% 
Signs of thyroid disturbances 0% 
malignancies 3% 
Palpitations 4% 
Pallor  30% 
Clubbing 4% 
Icterus 2% 
Pedal edema 7% 
Koilonychias 7% 
Glossitis  2% 
Aphthous ulcer 2% 
Lymphadenopathy 1% 
hepatomegaly 1% 
Splenomegaly 1% 
Tachycardia 9% 
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COMPARISON BETWEEN IRON PARAMETERS AND INTENSITY OF 
ANEMIA 
  Normal ferritin levels were seen in 20 mildly anemic patients, 19 
moderately anemic patients and 30 severely anemic patients. Ferritin levels were 
low in 4 mildly anemic, 10 moderately anemic and 8 severely anemic patients 
whereas increased ferritn levels was seen in 7 in the mildly anemic group, 10 in 
moderately anemic group and 8 in severely anemic group. 
Iron levels were normal in 21, 22, 13 patients among the mild, moderate 
and severely anemic respectively. Low iron was seen in 9 mildly anemic, 17 
moderately anemic and 16 severely anemic patients whereas only 1 patient in the 
mildly anemic group showed increased iron levels. 
Total iron binding capacity was normal in 16 patients with mild anemia, 
decreased in 8 and increased in 7 of the same group. The level of TIBC in 
moderately anemic patients was normal in 10, decreased in 11 and increased in 18 
patients. Among the severely anemic 5 had normal TIBC, 9 had decreased TIBC 
and 16 had increased TIBC. 
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CORRELATION OF PERIPHERAL SMEAR FINDINGS WITH 
INTENSITY OF ANEMIA 
Normocytic normochromic erythrocytes is seen in a total of 50 patients out 
of which 19 were mildly anemic patients, 21 were moderately anemic patients and 
10 were severely anemic patients. Microcytic hypochromic erythrocytes were 
found in a total of 44 patients of whom 10 were mildly anemic, 17 were 
moderately anemic and 18 were severely anemic patients. Dimorphic blood 
picture was seen totally 6 patients of whom 2 were mildly anemic, 1 was 
moderately anemic and 2 were severely anemic patients. 
Normal WBC counts were seen in 21 mildly anemic, 25 moderately 
anemic and 22 severely anemic patients whereas leucopenia was seen 1 ,mildly 
anemic, 3 moderately anemic, 2 severely anemia and leucocytosis was seen 9 
mildly anemic, 11moderately and 6 severely anemic patients. 
Platelet counts were normal in 92 patients of whom 27 were mildly 
anemic, 38 were moderately anemic and 27 were severely anemic. 
Thrombocytopenia was present in 4 patients of which they were 2 each in mildly 
and severely anemic group. Thrombocytosis was seen in 3 patients of which 2 
were mildly anemic and 1 patient was moderately anemic. 
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IMAGE 12. Photomicrograph showing peripheral smear with Normocytic 
Normochromic Red Blood Corpuscles (1000x, oil, leishman stain)  
 
 
 
 
 
 
 
 
 IMAGE 13. Photomicrograph showing peripheral smear with Microcytic 
Hypochromic Red Blood Corpuscles (1000x, oil, leishman stain)  
 
IMAGE 14. Photomicrograph showing peripheral smear with Dimorphic 
Blood Picture with Microcytic Hypochromic cells And Macrocytes                 
(1000x, oil, leishman stain)  
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DISCUSSION 
This study, conducted in a rural tertiary hospital, identified 100 old age 
persons with anemia (hemoglobin less than 13 gm/dl in men and less than 12 
gm/dl in women) who were included in the study. 
With regard to the various clinical features of anemia in old age in this 
study (table 7) the most common symptom was easy fatiguability which was seen 
in 75% of patients followed by peripheral edema seen in 10 % and palpitations in 
9 % of patients. These features corroborate closely with the results of the study by 
Amit Bhasin et al 2010[138]. The clinical signs seen in this study was pallor in 92 
%, peripheral edema in 21%, glossitis in 11%, koilonychia in 7%, hepatomegaly 
in 5 %  and splenomegaly in 6%. All the clinical signs were of higher incidence 
than that seen by Amit Bhasin et al 2010[138]  except peripheral edema which was 
similar in incidence.    
Regarding the age, the age in the present study population (table 1) ranged 
from 65 to 96 years with the mean age being 70.38. This mean age is similar to 
the studies conducted by Amit Bhasin et al 2010[138] , Chul Won Choi et al 
2003[139], slightly lower than that seen in study by Tettamanti M et al 2010[140] and 
Saurabh R Srivastava et al 2013[141]. In the present study the maximum number of 
patients were in the age group between 65 and 75 years comprising 85 % of the 
study population and this is similar to the study by Sfurti Mann et al 2014[142], 
Tettamanti M et al 2010[140] . The number of men (57 %) with anemia is higher 
than that of women (43 %)  with anemia in the present study (table 2)  and this 
similar to the studies conducted by Kaur et al 2013[143] and Chul Won Choi et al 
    73 
 
2003[139], and different from those by Tettamanti M et al 2010[140]  and Saurabh R 
Srivastava et al 2013[141], in which the percentage of women with anemia was 
found to be higher. 
The examination of peripheral smears in this study showed normocytic 
normochromic anemia to be the commonest seen in 50% of the patients which is 
similar to the study by Sfurti Mann et al 2014[142], Kaur et al 2013[143] and lower 
than that seen in Tettamanti M et al 2010[140]  and Chul Won Choi et al 2003[139], 
and higher than that seen by Saurabh R Srivastava et al 2013[141]. This is  followed 
by microcytic hypochromic anemia which was found in 44% of patients which is 
slightly higher than that seen in the study by Sfurti Mann et al 2014[142], Kaur et al 
2013[143]and significantly higher than that seen in study by Saurabh R Srivastava 
et al 2013[141],  Tettamanti M et al 2010[140]  and Chul Won Choi et al 2003[139] . 
Dimorphic anemia was seen in 6% of patients in this study which is slightly lower 
than that seen in study by Kaur et al 2013[143]and study by Sfurti Mann et al 
2014[142] . 
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Table 23 : Comparison of peripheral smear findings in the present study with 
other studies 
 PRESENT 
STUDY 
KAUR 
ET AL 
2013[143]
SFURTI 
MANN 
ET AL 
2014[142]
SAURABH R 
SRIVASTAVA 
ET AL 
2013[141]. 
TETTAMANTI 
M ET AL 
2010[140] 
CHUL 
WON 
CHOI ET 
AL 
2003[139],
MCHC 
ANEMIA 
44% 34% 40.40% 11.6% 72.3% 93.5% 
NCHC 
ANEMIA 
50% 56% 50% 69.8% 16.9% 3.5% 
DIMORPHIC 
ANEMIA 
6% 8% 10% 4.44% - - 
 
Regarding the various etiologies (table 5) for anemia the commonest cause 
in the present study was iron deficiency anemia which differed from other studies 
like NHANES III[9], Sfurti Mann et al 2014[142], Kaur et al 2013[143] , Tettamanti 
M et al 2010[140]  , Chul Won Choi et al 2003[139],  which show anemia of chronic 
disease to be the commonest cause. The second most common cause for anemia in 
the present study was anemia of chronic disease followed by anemia due to 
chronic kidney disease and unexplained anemia.  
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Table 24 : Comparison of etiology of anaemia in the present study with  
other studies 
 IDA ACD A-
CKD 
MEGALOBLASTIC 
ANEMIA 
UNEXPLAINED 
ANEMIA 
Present 
study 
43% 
 
32% 11% 1% 11% 
NHANES 
III 
14% 20% 8% 14% 34% 
Sfurti 
Mann et al 
2014[142], 
35% 41.66%  0.3% 0.6% 
Tettamanti 
M et al 
2010[140] 
16% 17.4% 15% 10.1% 26.4% 
Chul Won 
Choi et al 
2003[139], 
7% - - - - 
 
Regarding the iron parameters (table 15) in microcytic hypochromic 
anemia the ferritin values had a mean value of 61.75 µg/dl, in normocytic 
normochromic anemia it was 162.16 µg/dl and in dimorphic anemia it was 299 
µg/dl which varied from other studies. Sfurti Mann et al 2014[142] showed that 
mean ferritin values in microcytic hypochromic anemia was 70.58 µg/dl, in 
normocytic normochromic anemia was 424.67µg/dl and in dimorphic anemia was 
261.33µg/dl. Iron parameters in this study depending on etiology  (table 16) 
showed the ferritin levels varying from  that seen by Sfurti Mann et al 2014[142] as 
shown below. 
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Table 25 : Comparison of iron parameter in the present study with study by 
Sfurti Mann et al  
 IDA 
Present 
study 
IDA  
Sfurti Mann et 
al 2014[142], 
ACD 
Present study 
ACD  
Sfurti Mann et al 
2014[142], 
Ferritin µg/dl (mean) 23.58 17.38 220.51 504.2 
 
Of the 43 patients with iron deficiency anemia only 32 patients had peripheral 
smear showing the characteristic microcytic hypochromic picture even though the 
iron studies showed values suggestive of iron deficiency. Of the 43 patients only  
6 patients had history of GI bleed. Hence chronic blood loss could not be 
attributed to the iron deficiency and the deficiency is probably due to nutritional 
causes since almost all of the persons in the study population belong to the low 
socioeconomic status.   
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LIMITATIONS 
 
- Many patients could not produce previous imaging studies and laboratory 
parameters 
- B 12 and folate assay could not be done 
- Patients with unidentified etiology could not be evaluated further 
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CONCLUSION 
This study showed that the commonest cause for anemia among elderly 
patients is iron deficiency anemia followed by anemia due to chronic disease and 
also that it can be asymptomatic which is incidentally stumbled upon when one is 
evaluated for other symptoms. Not many clinical signs are consistent with anemia 
except for pallor even which can be absent in cases of mild anemia. Even though 
iron deficiency anemia is the commonest cause the peripheral smear studies in this 
study showed that normocytic normochromic picture was the commonest even 
when MCV levels were suggestive of microcytic anemia. Geriatric anemia is a 
disease that often goes unreported hence every effort should be made to identify 
the disease and evaluate the cause and it should not be ignored as merely being a 
part of ageing, for the consequences of anemia can have higher morbidity in the 
elderly.  
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 ANNEXURE I 
PROFORMA 
 
NAME 
AGE 
SEX 
ADDRESS 
OCCUPATION 
DURATION AND DETAILS OF ILLNESS 
SYMPTOMS                
• Easy fatiguability 
• Frequent falls 
• Dizziness 
• Tinnitus 
• Palpitations 
• Abdominal distention 
• Symptoms of thyroid disturbances 
• Recurrent infections 
PAST HISTORY 
• Diabetes 
• Hypertension 
• Coronary artery disease 
• Tuberculosis 
• Malignancies 
• Chronic kidney disease 
 
DRUG HISTORY 
PERSONAL HISTORY 
• Smoking 
• Alcoholism 
 GENERAL EXAMINATION 
• Pallor 
• Icterus 
• Pedal edema 
• Lymphadenopathy 
• Clubbing 
• Koilonychia 
• Glossitis 
• Angular stomatitis 
• Aphthous ulcers 
SYSTEMIC EXAMINATION 
CVS 
RS 
ABDOMEN 
CNS 
INVESTIGATIONS 
• CBC 
• ESR 
• Stool for occult blood 
• Blood urea 
• Serum creatinine 
• Liver function tests 
• Peripheral smear 
• Reticulocyte count 
• Serum ferritin 
• Serum iron 
• Total iron binding capacity 
• Imaging studies 
• Endoscopic studies ( if needed) 
 
 
 
 ஆராய்ச்சி தகவல் தாள் 
 
திᾞெநல்ேவᾢ மᾞத்ᾐவ கல்ᾥாி அரசு ெபாᾐமᾞத்ᾐவமைனக்கு 
வᾞம் 65 வயᾐக்கு ேமற்பட்ட ᾙதிய ேநாயாளிகᾦக்கு ஏற்பᾌம் 
இரத்தேசாைக பற்றிய ஒᾞ ஆராய்ச்சி நைட ெபற்ᾠவᾞகிறᾐ. 
ᾙதிய ேநாயாளிகᾦக்கு இரத்த ேசாைக என்பᾐ எவ்வளᾫ பரவலாக 
இᾞக்கிறᾐ என்பᾐ பற்றிᾜம், அதற்கான காரணங்கள் என்ன என்பᾐ 
பற்றிᾜம் அறிந்ᾐ ெகாள்வேத இந்த ஆராய்ச்சியின் ேநாக்கமாகும். 
நீங்கᾦம் இந்த ஆராய்ச்சியில் பங்ேகற்க நாங்கள் விᾞம்ᾗகிேறாம். 
ᾙᾊᾫகைள அல்லᾐ கᾞத்ᾐக்கைள ெவளியிᾌம் ேபாேதா அல்லᾐ 
ஆராய்ச்சியின் ேபாேதா தங்களᾐ ெபயைரேயா அல்லᾐ 
அைடயாளங்கைளேயா ெவளியிடமாட்ேடாம் என்பைதᾜம் ெதாிவித்ᾐக் 
ெகாள்கிேறாம். 
இந்த ஆராய்ச்சியில் பங்ேகற்பᾐ தங்கᾦைடய விᾞப்பத்தின் 
ேபாில்தான் இᾞக்கிறᾐ. ேமᾤம் நீங்கள் எந்ேநரᾙம் இந்த 
ஆராய்ச்சியிᾢᾞத்ᾐ பின்வாங்கலாம் என்பைதᾜம் ெதாிவித்ᾐக் 
ெகாள்கிேறாம். 
இந்த சிறப்ᾗப் பாிேசாதைனகளின் ᾙᾊᾫகைள ஆராய்ச்சியின் ேபாᾐ 
அல்லᾐ ஆராய்ச்சியின் ᾙᾊவில் தங்கᾦக்கு அறிவிப்ேபாம் என்பைதᾜம் 
ெதாிவித்ᾐக் ெகாள்கிேறாம். 
 
 
ஆராய்ச்சியாளர் ைகெயாப்பம்          பங்ேகற்பாளர் ைகெயாப்பம் 
  
 ஆராய்ச்சி ஒப்ᾗதல் கᾊதம் 
 
ஆராய்ச்சிதைலப்ᾗ: 65 வயᾐக்கு ேமற்பட்ட ᾙதிய ேநாயாளிகᾦக்கு 
ஏற்பᾌம் இரத்தேசாைக பற்றிய ஆராய்ச்சி. 
ெபயர்:  ேததி: 
வயᾐ:  உள்ேநாயாளிஎண்: 
பால்:           ஆராய்ச்சி  ேசர்க்ைக எண்: 
 
இந்த ஆராய்ச்சியின் விவரங்கᾦம் அதன் ேநாக்கங்கᾦம் 
ᾙᾨைமயாக எனக்கு ெதளிவாக விளக்கப்பட்டᾐ. எனக்கு விளக்கப்பட்ட 
விஷயங்கைள நான் ᾗாிந்ᾐ ெகாண்ᾌ எனᾐ சம்மதத்ைத ெதாிவிக்கிேறன். 
இரத்தேசாைக அறிகுறிகள் மற்ᾠம் பாதிப்ᾗகள் குறித்ᾐ 
ஆராய்ச்சியாளர் கூற ᾙᾨவᾐம் விளங்கப் ெபற்ேறன். 
இதற்குத் ேதைவயான உடற்பாிேசாதைனக்கும், இரத்தம் 
சம்பந்தப்பட்ட பாிேசாதைனகᾦக்கும் மனமார சம்மதிக்கிேறன். 
 
ைகெயாப்பம் 
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1 65 M C/O ABDOMINAL DISTENTION Y N Y N N Y Y N N N ND N N N Y N N N N N N N N Y Y 
2 70 F H/O FALLS,EASY FATIGUABILITY Y N N N Y N N N N N ND N N N Y N N N N N N N N N N 
3 65 M EASY FATIG, JOINT PAINS Y N N Y N N Y N N N ND N N N Y N N N Y Y N N N N N 
4 69 M COUGH,FEVER FOR 10 DAYS Y N N Y N Y Y Y Y N ND N N N Y Y N N N N N N N N N 
5 75 F FEVER,DYSPNOEA,LOOSE STOOLS Y N N Y N N N Y N N ND N N Y Y N N N N N Y N N N N 
6 80 M ALTERED SENSORIUM,OLIGURIA Y N Y Y N Y Y Y N N ND N N N Y N N Y N N N N N N N 
7 65 F COUGH,FEVER FOR 10 DAYS Y N N N N N N N N N ND N Y Y Y Y N N N N N N N N Y 
8 73 M REVIEW Y N N Y N N N N N N ND N Y Y Y N N Y N N N Y N Y N 
9 67 F PARAPARESIS Y N N Y Y N N N Y N ND N N Y Y N N N Y N N N N N Y 
10 70 F REVIEW Y N N N N N N N N N ND N Y N Y N N N Y N N Y N N N 
11 68 F FEVER, COUGH FOR 10 DAYS Y N N Y N N N Y N N ND N N N Y N N N N N Y N N N N 
12 69 F INGUINAL LYMPHADENOPATHY Y N N N N N N N N N ND N Y N Y N N Y Y N N Y N N N 
13 71 M DYSPNOEA,COUGH EXPECTORATION Y N N Y N Y Y N N N ND N N Y Y Y N N N N N N N N N 
14 73 M COUGH DYSPNOEA Y N N Y N N N Y Y N ND N Y N Y Y N N N N N N N N N 
15 69 M DYSPNOEA,COUGH EXPECTORATION N N Y Y N Y Y N N N ND N N N Y Y N N N N N N Y N N 
16 65 F LUMP BREAST FOR 6 MONTHS Y N N N N N N Y N N ND N Y N Y N N N Y N N Y N N N 
17 74 F LUMP BREAST FOR 3 YEARS Y N N N N N N N N N ND N Y N N N N N N N N Y N N N 
18 96 M GIDDINESS, N N N Y N N N Y N N ND N N N Y N N N N Y Y N N N N 
19 65 M PEDAL EDEMA FOR 20 DAYS Y N N Y N Y Y Y Y Y ND N N N Y N N Y N N N N N N N 
20 70 F ACCIDENTAL FALL FRACTURE Y N N N Y N N N N N ND N N Y Y N N N N N N N N N N 
21 70 F FEVER WITH CHILLS FOR  10 DAYS Y N N N N N N N N N ND N N N Y N N N N N N N N N N 
22 80 M SCROTAL SWELLING AND PAIN N N N Y N Y Y Y N N ND N N N Y N N Y N N N N N N N 
23 70 M COUGH EXPECTORATION FEVER 2 WKS Y N N Y N Y Y Y Y N ND N Y N Y Y N N N N N N N N N 
24 71 M GIDDINESS ON AND OFF Y N N N N N N N N N ND Y N N Y N N N N N N N N N N 
25 70 M APHASIA, FOCAL SEIZURES N N N N N N N Y Y N ND N N N Y N N N N N N N N N N 
26 65 F MASS PV THYROID LUMP Y N N N N N N N N N ND Y N N Y N N N N N N N N N N 
27 80 M R HEMIPLEGIA N N N N N N N Y Y N ND N N N Y N N N N N N N N N N 
28 66 M COUGH DYSPNOEA FEVER N N N N N Y Y Y N N ND N N N Y Y N N N N N N N N N 
29 67 F NASAL MASS N N N Y N N N N N N ND N N N Y N N N N N N N N N N 
30 70 M EASY FATIGUABILITY FEVER Y N N N N N N Y Y N N N N N Y N N N N N N N N N N 
31 65 M PEDAL EDEMA ABD.DISTENTION Y N Y Y N N N Y Y Y N N N N Y N N Y N Y N N N N N 
32 67 F THYROMEGALY L VOCAL CORD PALSY N N N N N N N N N N ND Y N N Y N N N N N N N N N N 
33 70 F ACCIDENTAL FALL FRACTURE TIBIA Y N N N N N N N N N ND N N Y Y N N N N N N N N N N 
34 68 M RTA HEMIATHROPLASTY 2 YRS BACK N N N N N N N N N N ND N N N Y N N N N N N N N N N 
35 70 F ACCIDENTAL FALL FRACTURE Y N N N N N N Y Y Y ND N N N Y N N N N N N N N N N 
36 80 M ASSAULT FRACTURE  N N N N N N N N N N ND N N N N N N N N N N N N N N 
37 65 M LOC, APHASIA, DROOLING Y N Y Y N N N N N N ND N N N Y N N N N N N N N N N 
38 80 M GIDDINESS, TINNITUS N N N Y N N N Y Y Y ND N N N N N N N N N N N N N N 
39 65 M GIDDINESS FALL HEMETEMESIS Y Y Y Y Y Y Y N N N Y N N N Y Y Y N N N N N N Y N 
40 67 F SWELLING R SIDE JAW 1 MONTH Y N Y Y N N N N N N ND N Y N Y N N N N N N N N N N 
41 78 M K/C/O CKD DYSPNOEA Y N Y Y N N N Y Y Y ND N N N Y N N Y N Y N N N N N 
42 67 F FEVER DYSURIA Y N N N N N N N N Y N N N N Y N N Y N Y Y N N N N 
43 73 F ULCER R THIGH  Y N N Y N Y Y N N N ND N N N Y N N N N N N N N N N 
44 70 M ABDOMINAL PAIN VOMITTING Y Y N N N Y Y Y Y N Y N Y N Y N N N Y Y Y N N N N 
45 65 F LUMP BREAST 4 MONTHS Y N N N N N N N N N ND N N N N N N N N N N Y N N N 
46 65 M PAIN ABDOMEN VOMITING Y ? N Y N Y Y Y Y N N N N N Y N N N N N N N N N N 
47 75 M FEVER, VOMITING,PAIN ABD N N N Y N N N Y Y N ND N N N Y N N N N N N N N N N 
48 68 M ACUTE CORONARY SYNDROME Y N N Y N N N Y Y N ND N N N Y N N N N N N N N N N 
49 65 M EASY FATIG, MALENA Y Y Y Y Y Y Y N N N Y N N N Y N N N N N N N N N N 
50 70 M DYSPNOEA,COUGH EXPECTORATION Y N N Y N Y Y N N N ND N N N Y Y N N N N N N N N N 
51 70 M ABDOMEN DISTENTION, Y N Y Y N Y Y N N N N N N N Y Y N Y N N N N Y N N 
52 68 F PEDAL EDEMA,DYSPNOEA Y Y N Y N N N Y Y Y Y N N N Y N N Y N N N N N N N 
53 65 F GIDDINESS,DYSPNOEA Y N Y N N N N N N N ND N N N Y N N N N N N N Y Y N 
54 68 F DYSPNOEA,K/C/O CAD Y N Y Y N N N Y Y N ND N N N Y N N N N N N N N N N 
55 72 F K/C/O DCLD Y Y Y N N N N N N N N N N N Y N Y Y N Y N N Y Y Y 
56 65 F K/C/O CKD DYSPNOEA Y N N Y N N N N N Y ND N N N Y N N Y N N N N N N N 
57 70 M PARAPERESIS Y N N Y N N N Y Y N ND N N N Y N N Y N N N N N N N 
58 70 F K/C/O CARCINOMA CERVIX Y N N N N N N N N N ND N Y N Y N N N Y Y Y N N N N 
59 72 M K/C/O CKD ANASARCA Y N Y Y N N N Y Y Y ND N N Y Y N N Y N N N N N N Y 
60 70 F COUGH FEVER DYSPNOEA Y N N N N N N N N N N N N N Y N N N N N N N N N Y 
61 68 M EASY FATIGUABILITY  Y N N N N Y Y Y Y N N N N N Y N N N N N N N N N N 
62 76 F FEVER DYSURIA Y N N N N N N N N N ND N N N Y N N N N Y N N N N Y 
63 63 F R SIDE HEMIPLEGIA Y N N Y N N N Y Y N ND N N N Y N N N N N N N N N N 
64 70 F EASY FATIGUABILITY, K/C/O AF Y N N Y Y N N N N N ND N N Y Y N N Y N N N N N N Y 
65 70 M FEVER DIARRHOEA DYSURIA Y N Y N N N Y N N N ND N N N Y Y N Y N N N N N N Y 
66 65 M FEVER DYSPNOEA Y N Y Y N N N Y Y Y ND N N N Y N N Y N N N N N N Y 
67 70 M K/C/O COPD N N N Y N Y Y N N N ND N N N Y N N N N N N N N N N 
68 75 M VOMITING DYSPHAGIA Y Y N N N Y Y N N N N N Y N Y N N N N N N N N N Y 
69 65 M FEVER, CLINICAL MALARIA N N N N N N N N N N N N N N Y N N N N N N N N N N 
70 70 M DYSPEPSIA N Y N Y N Y Y N N N Y N N N Y N N N N N N N N N N 
71 71 M K/C/O PT RELAPSE Y N N Y N Y Y N N N ND N N N Y Y N N N N N N N N N 
72 70 F K/C/O CARCINOMA OVARY Y N Y N N N N N N N ND N Y N Y N N Y N N Y N N N Y 
73 68 F FEVER COUGH NEW PT N N N N N N N Y Y N ND N N N Y N N N N N N N N N N 
74 69 F K/C/O PT COMPLETED ATT Y N N Y N N N N N N ND N N N Y Y N N N Y N N N N N 
75 65 F FEVER DYSURIA N N N N N N N Y Y N ND N N N Y N N Y N Y N N N N N 
76 68 F RLOIN PAIN DYSURIA N N N N N N N N N N ND N N N Y N N N N N N N N N N 
77 75 M URINARY RETENTION POLYURIA N N N N N N N N N N ND N N N Y N N N N N N N N N N 
78 76 M K/C/O CKD Y N Y N N N N N N N ND N N N Y N N N N N N N N N N 
79 80 M FALL INTERTROCHANTERIC FRAC N N N N Y N N N N N ND N N N N N N N N N N N N N N 
80 70 M HEMETEMESIS,MALENA Y Y N N N N N N N N Y N N N Y N N N N N N N N N N 
81 75 M EPISTAXIS N N N Y N N N N Y N N N N N N N N N N N N N N N N 
82 78 M R HYPOCHONDRIAC PAIN FEVER N N N N N N N N N N ND N N N N N N N N N N N N N N 
83 65 F GIDDINESS FALL HEMIPARESIS Y N N Y N N N Y Y N ND N N N Y N N N N N N N N N N 
84 65 M DYSPNOEA COUGH Y N N N N Y Y N N N ND N N N Y Y N N N N N N N N N 
85 74 M K/C/O DCLD HEMETEMESIS Y Y Y N N Y Y Y Y N Y N N N Y N Y N N N N N N Y Y 
86 72 F BEHAVIOURAL DISTURBANCES N N N N Y N N N N N ND N N N N N N N N N N N N N N 
87 65 F ABDOMEN PAIN VOMITING Y N N N N N N Y Y N N N N N Y N N N N N N N Y N N 
88 65 F GIDDINESS Y N N N N N N N N N ND N N N Y N N N N N N N N N N 
89 65 F K/C/O PEMPHIGUS VULGARIS Y N N N N N N N N N ND N N N Y N N N N N N N N N N 
90 74 M INGUINAL LYMPHADENOPATHY Y N N N N N N N N N ND N N N Y N N N N N N N N N N 
91 65 M RECURRENT FEVER  Y N N N N Y Y N N N ND N Y N Y N N N N N N N N N N 
92 80 M FALL INTERTROCHANTERIC FRAC N N N N N N N N N N ND N N N Y N N N N N N N N N N 
93 72 M K/C/O CARCINOMA RECTUM Y Y N N N Y Y N N N Y N N N Y N N N N N N Y N N N 
94 70 M ETHMOIDAL POLYP OPERATED N N N N N N N N N N ND N N N Y N N N N N N N N N N 
95 66 F FEVER DIARRHOEA  Y N N N N N N Y Y N N N N N Y N N N N N N N N N N 
96 76 F FUNGATING MASS R BREAST Y N N N N N N N N N ND N Y N Y N N N N N N Y N N N 
97 87 M GIDDINESS TINNITUS Y N N N N N N N N N ND N N N Y N N N N N N N N N Y 
98 70 M PEDAL EDEMA OLIGURIA Y N Y N N Y Y N N N ND N N N Y N Y Y N N N N N N N 
99 72 M DYSPNOEA Y N N N N Y Y N N N ND N N N Y Y N Y N N N N N N N 
100 67 F CHEST DISCOMFORT Y N N N N Y Y N N N ND N N N Y N N N N N N N N N Y 
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ULTRASONOGRAM 
1 12 7.14 23800 78/13/2 39 5.73 10 64 18 23 13.2 2.6 46.9 30 346 NORMAL NORMAL SPLENOMEGALY WITH NORMAL PORTAL VEIN THICKNESS 
2 5.8 3.9 5200 66/25/7 23 3.74 142 54 16 28 23.2 0.4 50.3 14 542 NORMAL NORMAL NORMAL STUDY 
3 6.7 3.7 4700 64/31/2 34 1.46 115 72 18.1 25 20.2 0.8 3 10 633 NORMAL NORMAL NORMAL STUDY 
4 10.7 3.37 4900 65/20/15 30.2 1.28 105 90.8 31.8 33.2 14.2 1.1 360 60 372.8 ELEVATED NORMAL CHRONIC KIDNEY DISEASE,PROSTATOMEGALY 
5 10.1 3.82 20500 90/8/5 29.9 7300 132 76 25.8 33.8 16.6 1 86 16.88 55.32 22/1.1 NORMAL NORMAL STUDY 
6 6.6 2.73 4300 69/20/11 21.8 1.11 40 79.9 24.2 30.3 13.3 1.2 330.83 37.25 177.03 22/1.1 NORMAL PARENCHYMAL LIVER DISEASE WITH PHT, 
7 9.7 3.66 15200 80/5/15 23 2.73 44 80.3 26.5 33 14.2 0.6 223.3 56.2 123.9 NORMAL NORMAL NORMAL STUDY 
8 10 3.44 43000 30/68/2 31 1.35 23 90 31.7 35.2 13.9 1.8 341.9 43.2 221.1 NORMAL NORMAL SPLENOMEGALY 
9 5.1 3.42 11900 61/31/7 20 1.3 50 53.6 13.6 25.6 24.7 0.82 25.73 131 325.9 NORMAL NORMAL NORMAL STUDY 
10 10 3.3 6200 64/27/9 30.4 2.83 30 92.1 30.9 33.6 13.3 0.5 86.9 65.87 445.8 NORMAL NORMAL NORMAL STUDY 
11 6.6 2.05 2600 34/55/11 18.9 6000 40 92 32.2 34.9 20.2 1.01 225 84.05 117.36 NORMAL NORMAL NORMAL STUDY 
12 10.3 3.87 9200 65/28/7 34.8 2.64 10 88.1 30.2 34.2 12.7 1.49 273.8 58.96 120 NORMAL NORMAL NORMAL STUDY 
13 12 5.03 13200 76/20/4 39.4 2.22 15 78.3 23.9 30.5 15.3 0.2 36.66 50.6 168.63 NORMAL NORMAL NORMAL STUDY 
14 11.4 3.96 8500 68/18/14 34.2 3.08 40 86.4 28.8 33.3 18.2 0.86 296.6 27.09 72.48 NORMAL NORMAL NORMAL STUDY 
15 4.2 2.1 8500 74/17/9 17.5 4.8 110 83.5 20 24 20.1 0.44 27.43 57.51 138 NORMAL NORMAL HEPATOMEGALY 
16 10.1 6.3 7700 48/47/5 55.8 1.53 10 87.5 26.8 30.6 14.9 0.67 149.77 63.79 59.85 NORMAL NORMAL NORMAL STUDY 
17 10.1 3.82 6400 67/26/7 31.3 3.52 115 81.9 26.4 32.2 15.2 2.06 51.22 57.35 179.07 NORMAL NORMAL NOT DONE 
18 8.1 3.76 8900 74/16/10 28.8 2.34 60 76.5 24.7 32.3 17.4 1.4 18.45 24.83 549.67 51/1.8 NORMAL CHOLELITHIASIS 
19 9 3.29 8000 66/24/10 25.7 2.92 40 78.1 27.4 35 14.4 0.2 282.3 88 131.52 NORMAL NORMAL GALL BLADDER CALCULI 
20 6.8 3.3 6500 73/20/7 20 1.65 60 70.3 26.6 32 17.8 1.02 18.73 9.14 507.22 NORMAL NORMAL NORMAL STUDY 
21 7.1 3.25 14500 88/8/3 24 4.7 90 73.8 21.8 29.6 20.6 1.05 21.2 19.84 462.19 NORMAL NORMAL SPLENIC ABCESS 
22 11.3 3.51 9500 83/11/5 34.4 3.53 25 98 32.2 32.8 14.9 1.7 12.62 37.04 122.97 NORMAL NORMAL MINIMAL FLUID IN LOWER ABDOMEN 
23 10.8 4.72 8000 80/9/9 33.2 5.11 28 70.3 22.9 32.5 13.4 1.7 191 70.23 142.59 NORMAL NORMAL NOT DONE 
24 11 4.12 7000 64/26/8 38.5 2.46 15 93.4 29.1 31.2 13.8 0.18 385.7 28.52 324.9 NORMAL NORMAL NOT DONE 
25 10.3 3.54 7400 77/13/8 30.2 2.8 15 85.3 29.1 34.1 12.6 0.93 57.05 21.92 355.2 NORMAL NORMAL NOT DONE 
26 7.9 4.37 5800 65/23/11 28 2.5 10 65.7 18.1 27.5 28.6 1.3 4.86 16.16 588.9 NORMAL NORMAL NORMAL STUDY 
27 8.7 3.5 6700 74/16/9 29.4 2.25 45 81.9 24.2 29.6 16.8 0.63 28.4 68.57 96.48 NORMAL NORMAL NORMAL STUDY 
28 9.7 3.5 13300 85/7/6 25.3 1.78 20 79.2 27.6 34.9 12.4 1.36 223.1 48.4 266.64 NORMAL NORMAL NOT DONE 
29 11 4.6 6800 67/25/6 29 3.44 2 38.8 26.6 38.8 13.7 0.84 18.1 48.07 456.9 NORMAL NORMAL NOT DONE 
30 5.6 2.39 6000 76/12/10 24.5 1.43 30 77.8 23.4 30.1 24 0.43 5.34 16.16 530.8 NORMAL NORMAL NORMAL STUDY 
31 9.4 3.21 14500 70/27/2 27.8 2.91 30 86.6 29.3 33.8 14.7 1.71 41.3 15.64 151.75 80/2.1 NORMAL MRD GR I, PROSTATOMEGALY 
32 11 4.02 9800 50/36/14 33 2.5 20 84.3 28.9 33.9 12.8 1.9 60.2 79.22 282.32 NORMAL NORMAL NOT DONE 
33 6.3 2.2 5400 60/30/9 19.8 3.84 65 90 28.6 31.8 16.8 0.68 53.89 85.04 343.5 NORMAL NORMAL NOT DONE 
34 8.4 2.98 6900 78/11/10 25.1 1.56 45 84.2 28.2 33.5 13.7 1.34 6.55 5.09 551.5 NORMAL NORMAL NORMAL STUDY 
35 8.9 3.28 5000 58/29/2 27.1 2.51 20 82.6 27.1 32.8 13.8 0.78 50.74 60.31 160.3 62/1.5 NORMAL GALL BLADDER CALCULI 
36 12 3.87 5300 64/26/9 37 2.39 20 95.6 33.9 35.4 13.3 2.3 48.6 37.3 351.3 NORMAL NORMAL NORMAL STUDY 
37 6.6 3.7 3700 66/24/9 23.6 9500 43 70 19.6 28 22 1.2 46.37 28.91 523 NORMAL NORMAL NORMAL STUDY 
38 12 4.64 15000 77/15/7 39.9 2.27 2 86 31.9 37 13.5 2.1 63.12 18.49 424.8 NORMAL NORMAL MRD GRADE I, PROSTATOMEGALY 
39 8.1 2.58 6100 53/23/23 23.1 1.28 10 89.5 31.4 35.1 16.2 0.83 10.68 54.08 360.9 NORMAL ELEVATED SPLENOMEGALY, DCLD WITH PHT 
40 11 4.22 5100 56/31/10 35.4 2.1 2 83.9 28.7 34.2 12.8 1.9 40.42 197.3 218.49 NORMAL NORMAL NORMAL STUDY 
41 8.9 3.17 9200 71/28/ 26.5 2.23 25 83.6 28.1 33.6 15.4 1.12 12.38 8.57 552.3 160/5.7 NORMAL MRD GRADE IV 
42 7 2.55 7700 78/15/7 21.4 1.97 140 83.9 27.5 32.7 14.9 0.93 124.1 60.4 68.73 105/3.6 NORMAL GRADE IV MRD 
43 9.9 3.78 6300 75/17/8 32.3 2.01 150 85.4 26.2 30.7 19.4 0.72 61.9 18.81 331.8 46/1.4 NORMAL GRADE I MRD 
44 8.9 3.54 6700 75/17/8 30.2 1.52 110 82.3 25.2 30.7 16.2 0.85 255.8 32.3 402.7 43/1.3 NORMAL ANTRAL WALL THICKENING 
45 11 4.93 7600 71/22/6 40.7 2.67 22 82.6 28.8 34.9 13.1 1.8 615.9 34.96 352.2 NORMAL NORMAL NOT DONE 
46 6.6 4.2 4600 60/18/22 21.9 1.08 42 79.9 24.1 30.1 24.1 0.82 251.1 22.77 73.56 NORMAL NORMAL NORMAL STUDY 
47 9.4 3.65 3400 85/10/5 28.1 2.62 45 77 25.8 33.5 15 0.38 31.07 54.3 431.74 65/1.2 NORMAL NORMAL STUDY 
48 6.4 4.07 5900 76/16/7 24.4 4.83 35 59.5 15.7 26.4 19.3 0.77 28.84 17.45 509.41 NORMAL NORMAL CHOLELITHIASIS 
49 4.6 2.83 2400 62/26/10 18.4 4.25 15 65 16.3 25 21.3 0.31 13.3 45.9 678 NORMAL NORMAL NORMAL STUDY 
50 11 4.83 9800 83/13/1 39.1 3.6 15 81 26.3 32.5 14 0.93 53.14 58.2 382.3 NORMAL NORMAL NORMAL STUDY 
51 7.4 3.91 2400 59/28/12 26.9 1.06 10 68.8 18.9 27.5 21 1.3 28.9 27.38 486.9 NORMAL NORMAL IVF DILATED 
52 6.8 3.03 6800 59/29/11 21.7 3.75 20 71.6 22.4 31.3 20.5 1.2 50.25 9.09 427.5 48/1.6 NORMAL NORMAL STUDY 
53 7.1 2.59 2400 27/70/3 21.9 1.79 120 84.6 27.4 32.4 19.7 0.94 19.9 26.2 542.2 NORMAL NORMAL HEPATOSPLENOMEGALY 
54 7 2.57 2500 62/30/8 21.8 1.71 20 84.8 27.2 32.1 19.9 0.44 42.48 15.9 253.04 NORMAL NORMAL NORMAL STUDY 
55 9.6 3.35 4700 60/21/7 28.5 5.8 10 85.1 28.7 33.7 14.7 1.21 10.2 80.8 450.4 NORMAL ELEVATED HEPATOSPLENOMEGALY 
56 9.7 3.35 10600 69/19/11 26.5 3.05 20 79.1 29 36.6 12.9 0.63 142.8 82.9 80.58 50/2.9 ELEVATED GRADE II RENAL PARENCHYMAL DISEASE 
57 6.8 2.28 7000 87/9/3 19.3 2.25 115 84.6 29.8 35.2 16 0.93 56.6 68.9 356.9 107/2 NORMAL FATTY LIVER, RPD 
58 8.8 4.37 8300 72/16/12 29.7 3.74 44 76.3 26.2 27.3 16.6 0.73 178.9 32.9 156.9 NORMAL NORMAL NORMAL STUDY 
59 3.8 2.06 7500 75/15/10 13.8 3.93 54 67 18.4 27.5 15.5 0.43 332.2 24.9 131.9 115/2.3 NORMAL GRADE IV MEDICAL RENAL DISEASE, ASCITES 
60 6.8 3.57 7500 89/13/7 23 3.16 105 64.4 19 29.6 20.2 1.2 13.1 17.9 668.4 NORMAL NORMAL NORMAL STUDY 
61 6.1 3.8 6900 73/24/3 22.3 2.26 56 78.3 27.3 27 26.3 1.8 24 58.9 480.9 NORMAL NORMAL PROSTATOMEGALY 
62 4.3 2.01 4800 55/28/17 14.9 2.96 32 74 21 28 28.4 2.1 19.5 41.3 567.8 NORMAL NORMAL NORMAL STUDY 
63 7.3 4.2 6500 68/20/12 28.3 1.68 30 80.6 28.3 37 13.3 3.4 179 26.6 187 NORMAL NORMAL NOT DONE 
64 2.4 2.46 6700 73/24/3 13.3 1.8 108 61 16.7 27.3 20.6 0.34 20.9 43.6 654.3 NORMAL NORMAL NOT DONE 
65 6.7 2.03 10600 89/6/4 14.2 76000 56 108 33 35.8 23 1.1 299 87.9 176.8 58/2 NORMAL GRADE I RPD 
66 10.8 3.98 15500 87/6/6 26.9 2.13 45 72.9 27.1 37.2 13.3 2.1 278.5 58.9 203.8 173/3.8 NORMAL GRADE IV MEDICAL RENAL DISEASE, ASCITES 
67 9.6 2.8 6700 54/28/16 22.4 1.71 33 91.3 33.3 36.5 12.7 2.1 343.9 43.2 176.9 NORMAL NORMAL NOT DONE 
68 5.7 1.86 6100 70/20/9 15 1.92 106 87.1 30.6 35.2 13.3 1.2 543.5 33.2 123.2 NORMAL NORMAL NORMAL STUDY 
69 10.8 3.4 9400 76/14/9 29 2.4 38 83.8 31.2 37.2 12.9 2.2 45.4 78.2 243.8 NORMAL NORMAL NORMAL STUDY 
70 9.5 3.9 9200 78/13/7 28.9 3.96 45 81.7 29.1 35.6 15.5 1.8 299.9 76.9 387.9 NORMAL NORMAL NORMAL STUDY 
71 8.6 3.8 13400 78/12/10 25.6 2.23 58 85.6 28.6 32.7 14.4 1.5 376 49.6 298.9 NORMAL NORMAL NORMAL STUDY 
72 7.6 2.3 6800 80/10/10 15.9 1.45 82 68.3 24.2 28.3 18.9 0.56 20.8 43.2 567.1 NORMAL NORMAL MINIMAL ASCITES 
73 10 3.6 12000 57/35/8 22.8 2.2 92 79 29.7 30.4 14.8 1.1 34.2 56.1 354.9 NORMAL NORMAL NORMAL STUDY 
74 9.3 4.3 14000 68/20/12 28.4 3.25 54 74.3 28.3 33.3 16.38 1.3 16.7 54.2 455.1 NORMAL NORMAL NORMAL STUDY 
75 10.5 3.8 10600 75/20/5 26.9 1.68 20 63.3 20.6 28.3 23.6 0.54 43.2 55.3 234.3 NORMAL NORMAL NORMAL STUDY 
76 10.5 4.1 11000 70/20/10 27.8 2.25 23 75.5 23.6 29.4 16.2 0.65 9.87 11.2 487.9 NORMAL NORMAL LEFT LOWER URETERIC CALCULUS 
77 9.6 3.63 6500 58/30/12 25 3.63 32 74 28.7 32.3 18.8 0.89 27.6 57.2 434.2 NORMAL NORMAL PROSTATOMEGALY 
78 9.2 4.63 7000 68/14/18 28.3 1.86 40 89.4 29.6 32.4 14.6 1.2 245.6 30.4 176.2 67/2.6 NORMAL GRADE IV MEDICAL RENAL DISEASE, ASCITES 
79 10.3 3.84 8500 75/20/5 39.3 1.68 68 63.2 26.4 33.2 22.1 2.1 25.7 33.4 456.1 NORMAL NORMAL NORMAL STUDY 
80 8.9 3.86 12000 65/30/5 16 5.68 50 88.3 29.4 35.4 12.2 1.5 27.7 54.4 451.1 NORMAL NORMAL NORMAL STUDY 
81 11 4.83 9000 68/30/2 29.2 5.8 20 92.3 30.4 37.3 14.3 0.82 45.2 88.5 364.9 NORMAL NORMAL NORMAL STUDY 
82 10.5 3.82 6700 70/20/10 35.3 1.33 25 70.3 26.4 32.3 17.8 1.9 23.2 54.2 545.2 NORMAL NORMAL CHOLELITHIASIS 
83 5.3 2.23 6500 80/10/10 19.2 2.64 60 53.2 18.4 23.2 28.9 0.32 10.9 23.2 672.1 NORMAL NORMAL NORMAL STUDY 
84 6.8 3.3 13400 82/10/8 25 1.64 60 86 26.3 30.3 16.2 0.63 555.2 78.3 122.1 NORMAL NORMAL NORMAL STUDY 
85 6.4 3.8 7600 81/17/2 22.3 4.68 70 75.6 27.4 32.4 18.8 0.72 23.4 22.2 325.9 NORMAL ELEVATED SPLENOMEGALY WITH PHT 
86 10.4 3.61 6500 69/23/8 28.2 1.8 30 82.5 28.8 34.9 15.4 1.8 12.9 13.2 455.2 NORMAL NORMAL NOT DONE 
87 9.7 3.38 9200 68/27/4 26 1.09 32 85.8 28.7 33.4 16.2 1.2 34.3 43.2 234.1 NORMAL NORMAL HEPATOMEGALY,CHOLEDOCHOLITHIASIS 
88 8.5 3.18 8800 60/31/9 20 3.5 40 77 26.7 34.7 19.8 0.87 12.9 23.2 433.4 77/2.5 NORMAL NORMAL STUDY 
89 5.4 1.97 10000 70/20/10 15.6 2.5 56 65.8 27.4 34.6 15.6 0.23 16.2 19.6 545.9 NORMAL NORMAL NOT DONE 
90 7.9 3.48 16500 80/15/5 28.3 1.82 82 81.4 25.2 33 19.3 1.1 556.4 96.9 234.2 NORMAL NORMAL NORMAL STUDY 
91 3.3 1.28 28600 23%BLAST 18.3 1.2 86.2 28.2 35 90 18.3 0.68 243.2 34.2 234.1 NORMAL NORMAL HEPATOMEGALY 
92 8.8 3.2 9800 72/25/5 28 1.3 18 89.1 29.3 34.8 14.2 0.93 78.2 56.9 342.2 NORMAL NORMAL NORMAL STUDY 
93 7.5 3.7 15000 73/24/3 21 2.26 82 88.3 29.2 33.4 13.7 1.3 333.4 56.6 123.4 NORMAL NORMAL PARAAORTIC LYMPH NODES ENLARGED 
94 10 3.9 5800 75/20/5 29.7 2.28 33 76.4 24.2 30.1 19.7 1.6 37.7 89.2 342.9 NORMAL NORMAL NORMAL STUDY 
95 9.8 3.2 11500 80/15/5 19.6 1.78 43 65.2 22.1 28.2 23.9 0.87 13.6 25.8 478.9 NORMAL NORMAL NORMAL STUDY 
96 6.8 2.9 6900 83/10/7 23.9 2.89 98 89 28 32 15.6 0.9 349.5 66.8 167.2 NORMAL NORMAL NORMAL STUDY 
97 6.7 3.3 5400 65/32/3 22 1.9 43 65 21 23 21.8 1.1 24.2 33.2 453.9 NORMAL NORMAL NORMAL STUDY 
98 7.9 2.76 6000 59/31/11 24.6 1.84 37 87.4 25.9 33.7 13.7 1.6 23.2 34.3 439.2 NORMAL ELEVATED DCLD ASCITES 
99 4.5 2.5 6000 67/22/11 16 1.99 62 80.3 26.9 31 14.9 0.98 33.2 54.2 527.6 NORMAL NORMAL ASCITES WITH FATTY LIVER 
100 7.4 2.8 7800 67/30/3 22.8 2.3 62 68.9 23.9 29.8 19.9 1.1 23.9 43.3 458.9 NORMAL NORMAL NORMAL STUDY 
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PERIPHERAL SMEAR CHEST XRAY CT SCAN OTHER INVESTIGATIONS DIAGNOSIS 
1 NCNC MODERATE ANISOPOIKILOCYTOSIS,WBC NORMAL, EOSINOPHILIA, THROMBOCYTOSIS NORMAL NORMAL 
SERUM ELECTROPHORESIS- Β 
THALASSEMIA TRAIT 
Β THALASSEMIA 
TRAIT 
2 
MCHC,MOD AIP, 
MACROCYTES,STOMATOCYTES,ELLIPTOCYTES,WBC 
PLATELETS NORMAL 
NOT DONE NOT DONE     - IRON DEFICIENCY ANEMIA 
3 
NCNC,MILD 
ROULEAUX,ELLIPTOCYTES,TRANSFORMED 
MONOCYTES, PLATELETS ADEQUATE 
NOT AVAILABLE NOT DONE     - IRON DEFICIENCY ANEMIA 
4 NCNC ANEMIA WBCS AND PLATELETS NORMAL NOT DONE NOT DONE     - ANEMIA OF CHRONIC RENAL DISEASE 
5 NCHC ANEMIA NEUTROPHILIA THROMBOCYTOPENIA NOT DONE NOT DONE     - 
ANEMIA OF 
UNEXPLAINED 
ETIOLOGY 
6 NORMOCYTIC NORMOCHROMIC RBCS WBCS AND PLATELETS NORMAL 
COSTOPHRENIC ANGLE 
OBLITERATED NOT DONE     - 
ANEMIA OF CHRONIC 
RENAL DISEASE 
7 NORMOCYTIC NORMOCHROMIC RBCS WBCS AND PLATELETS NORMAL MEDIASTINAL MASS MEDIASTINAL MASS 
BIOPSY OF MASS- THYMOMA TYPE 
B1 
ANEMIA OF CHRONIC 
DISEASE 
8 MICROCYTIC HYPOCHROMIC ANEMIA,CHRONIC MYELOID LEUKEMIA, THROMBOCYTOPENIA NOT AVAILABLE NOT DONE     - 
CHRONIC MYELOID 
LEUKEMIA 
9 SEVERE MCHC ANEMIA, WBC AND PLATELETS NORMAL NOT DONE NOT DONE     - 
ANEMIA OF 
UNEXPLAINED 
ETIOLOGY 
10 NORMOCYTIC NORMOCHROMIC RBCS WBCS AND PLATELETS NORMAL NOT AVAILABLE NOT DONE     - 
ANEMIA OF CHRONIC 
DISEASE 
11 MICROCYTIC HYPOCHROMIC RBCS ADMIXED WITH MACROCYTES,LEUCOPENIA,THROMBOCYTOPENIA NOT DONE NOT DONE     - 
ANEMIA OF CHRONIC 
RENAL DISEASE 
12 NORMOCYTIC NORMOCHROMIC RBCS WBCS AND PLATELETS NORMAL NOT DONE NOT DONE 
FNAC INGUINAL NODE- 
MALIGNANT MELANOMA 
METASTATIC DEPOSITS 
ANEMIA OF CHRONIC 
DISEASE 
13 MICROCYTIC HYPOCHROMIC RBCS WITH MILD ANISOPOIKILOCYTOSIS,NL, PLATELETS ADEQUATE R UPPER LOBE CALCIFICATION 
MASS R UL WITH 
CALCIFICATION 
FNAC- INFLAMMATORY SMEAR, 
BIOPSY MOD.DIFF SQUAMOUS 
ANEMIA OF CHRONIC 
DISEASE 
CELL CARCINOMA 
14 NORMOCYTIC NORMOCHROMIC RBCS WBCS AND PLATELETS NORMAL R UPPER LOBE OPACITY SEEN R UL MASS  
BRONCHOSCOPY- R UL MASS R 
MAIN BRONCHUS 2 CM DISTAL TO 
CARINA 
ANEMIA OF CHRONIC 
DISEASE 
15 NORMOCYTIC NORMOCHROMIC RBCS WBCS AND PLATELETS NORMAL 
THICKWALLED CAVITY LEFT 
LUNG APICAL REGION NOT DONE     - 
ANEMIA OF 
UNEXPLAINED 
ETIOLOGY 
16 NORMOCYTIC NORMOCHROMIC RBCS LYMPHOCYTOSIS, PLATELETS NORMAL NOT DONE NOT DONE 
BIOPSY AXILLARY NODE- 
METASTATIC DEPOSITS 
ANEMIA OF CHRONIC 
DISEASE 
17 NORMOCYTIC NORMOCHROMIC ANEMIA WBC AND PLATELETS NORMAL NOT DONE NOT DONE 
FNAC BREAST MASS- DUCTAL 
CARCINOMA GRADE III,,NODE- 
METASTATIC CARCINOMATOUS 
DEPOSITS 
ANEMIA OF CHRONIC 
DISEASE 
18 MICROCYTIC HYPOCHROMIC RBCS WITH MILD ANISOPOIKILOCYTOSIS,NL, PLATELETS ADEQUATE CARDIOMEGALY NOT DONE      - 
IRON DEFICIENCY 
ANEMIA 
19 NORMOCYTIC NORMCOCHROMIC ANEMIA WBCS AND PLATELETS NORMAL NOT DONE NOT DONE 
FUNDOSCOPY- MILD NON 
PROLIFERATIVE DIABETIC 
RETINOPATHY 
ANEMIA OF CHRONIC 
DISEASE 
20 MICROCYTIC HYPOCHROMIC ANEMIA, WBC AND PLATELETS NORMAL NOT DONE NOT DONE      - 
IRON DEFICIENCY 
ANEMIA 
21 SEVERE MCHC ANEMIA, NEUTROPHILIA, PLATELETS ADEQUATE NOT AVAILABLE NOT DONE      - 
IRON DEFICIENCY 
ANEMIA 
22 
MICROCYTIC HYPOCHROMIC ADMIXED WITH 
MACROCYTES HYPERSEG NEUTROPHILS PLATELET 
ADEQUATE 
NOT DONE NOT DONE      - 
NUTRITIONAL 
ANEMIA DUE TO 
IRON/B12/FOLATE 
23 MILD MICROCYTIC HYPOCHROMIC ANEMIA NEUTROPHILIA THROMBOCYTOSIS NOT DONE 
MASS WITH CENTRAL 
NECROSIS R 
LUNG,BRONCHIECTASIS 
FNAC - MEDIASTINAL MASS - 
POSITIVE FOR MALIGNANCY 
SUGGESTIVE OF SQUAMOUS CELL 
CARCINOMA 
ANEMIA OF CHRONIC 
DISEASE 
24 MILD MICROCYTIC HYPOCHROMIC ANEMIA WBC AND PLATELETS NORMAL NOT DONE NOT DONE      - 
ANEMIA OF 
UNEXPLAINED 
ETIOLOGY 
25 NORMOCYTIC NORMOCHROMIC ANEMIA WBC AND PLATELETS NORMAL NOT DONE NOT DONE      - 
ANEMIA OF 
UNEXPLAINED 
ETIOLOGY 
26 
MICROCYTIC HYPOCHROMIC RBCS WITH SEVERE 
ANISOPOIKILOCYTOSIS ADMIXED WITH 
NORMOCYTES 
NOT DONE NOT DONE TFT- SUGGESTIVE OF HYPOTHYROIDISM 
IRON DEFICIENCY 
ANEMIA 
27 MICROCYTIC HYPOCHROMIC RBCS ADMIXED WITH NORMOCYTIC RBCS NOT DONE THALAMIC HEMORRHAGE      - 
ANEMIA OF 
UNEXPLAINED 
ETIOLOGY 
28 NORMOCYTIC NORMOCHROMIC RBCS  NEUTROPHILIA PLATELETS ADEQUATE LUNG ABCESS NOT DONE 
BRONCHIAL WASH- 
INFLAMMATORY SMEAR 
ANEMIA OF 
UNEXPLAINED 
ETIOLOGY 
29 MICROCYTIC HYPOCHROMIC ANEMIA WBCS AND PLATELETS NORMAL NOT DONE NOT DONE      - 
IRON DEFICIENCY 
ANEMIA 
30 SEVERE MICROCYTIC HYPOCHROMIC ANEMIA WBCS AND PLATELETS NORMAL NORMAL STUDY NOT DONE      - 
IRON DEFICIENCY 
ANEMIA 
31 NORMOCYTIC NORMOCHROMIC ANEMIA,NEUTROPHILIA AND PLATELETS NORMAL NOT DONE NOT DONE      - 
ANEMIA OF CHRONIC 
RENAL DISEASE 
32 NORMOCYTIC NORMOCHROMIC RBCS LYMPHOCYTOSIS AND PLATELETS NORMAL NOT AVAILABLE NOT DONE      - 
ANEMIA OF CHRONIC 
DISEASE 
33 NORMOCYTIC NORMOCHROMIC RBCS WBCS AND PLATELETS NORMAL NOT DONE NOT DONE      - 
ANEMIA OF CHRONIC 
DISEASE 
34 MODERATE MICROCYTIC HYPOCHROMIC ANEMIA WBC AND PLATELETS NORMAL GRADE 3B BB FRACTURE R LEG NOT DONE      - 
IRON DEFICIENCY 
ANEMIA 
35 DIMORPHIC ANEMIA LYMPHOCYTOSIS PLATELETS ADEQUATE GARDEN TYPE III L SIDE NOT DONE      - 
ANEMIA OF 
UNEXPLAINED 
ETIOLOGY 
36 DIMORPHIC ANEMIA WBCS AND PLATELETS NORMAL 
R HIP PERIPROSTHETIC 
FRACTURE NOT DONE      - 
IRON DEFICIENCY 
ANEMIA 
37 SEVERE MICROCYTIC HYPOCHROMIC ANEMIA WBCS AND PLATELETS DECREASED NOT DONE LACUNAR INFARCT      - 
IRON DEFICIENCY 
ANEMIA 
38 NORMOCYTIC NORMOCHROMIC RBCS WBCS AND PLATELETS NORMAL NOT DONE NOT DONE 
ECG - POOR R WAVE PROGRESSION 
Q WAVES IN III, A VF 
IRON DEFICIENCY 
ANEMIA 
39 NORMOCYTIC NORMOCHROMIC RBCS WBCS AND PLATELETS NORMAL NOT DONE NOT DONE      - 
IRON DEFICIENCY 
ANEMIA 
40 DIMORPHIC ANEMIA LYMPHOCYTOSIS PLATELETS ADEQUATE 
OSTEOLYTIC LESION R SIDE OF 
JAW NOT DONE 
FNAC JAW LUMP- S/O 
OSTEOCLASTOMA 
ANEMIA OF CHRONIC 
DISEASE 
41 NORMOCYTIC NORMOCHROMIC RBCS LYMPHOCYTOSIS PLATELETS ADEQUATE NOT DONE NOT DONE     - 
IRON DEFICIENCY 
ANEMIA 
42 NORMOCYTIC NORMOCHROMIC RBCS WBCS AND PLATELETS NORMAL NOT DONE NOT DONE     - 
ANEMIA OF CHRONIC 
RENAL DISEASE 
43 NORMOCYTIC NORMOCHROMIC RBCS WBCS AND PLATELETS NORMAL NOT DONE NOT DONE     - 
IRON DEFICIENCY 
ANEMIA 
44 NORMOCYTIC NORMOCHROMIC RBCS WBCS AND PLATELETS NORMAL NOT AVAILABLE NOT DONE 
UGI SCOPY- PYLORIC CANAL 
GROWTH - BIOPSY TAKEN,POORLY 
DIFFERENTIATED 
ADENOCARCINOMA 
ANEMIA OF CHRONIC 
DISEASE 
45 NORMOCYTIC NORMOCHROMIC RBCS WBCS AND PLATELETS NORMAL NOT DONE NOT DONE     - 
ANEMIA OF CHRONIC 
DISEASE 
46 NORMOCYTIC NORMOCHROMIC RBCS WBCS AND PLATELETS NORMAL NOT DONE NOT DONE 
UGI SCOPY- ANTRAL GROWTH - 
BIOPSY - WELL DIFFERENTIATED 
ADENOCARCINOMA 
ANEMIA OF CHRONIC 
DISEASE 
47 MICROCYTIC HYPOCHROMIC ANEMIA NEUTROPHILIA AND PLATELETS NORMAL NORMAL STUDY NOT DONE     - 
IRON DEFICIENCY 
ANEMIA 
48 MICROCYTIC HYPOCHROMIC ANEMIA WBCS AND PLATELETS NORMAL NORMAL STUDY NOT DONE     - 
IRON DEFICIENCY 
ANEMIA 
49 MICROCYTIC HYPOCHROMIC ANEMIA LEUCOPENIA PLATELETS ADEQUATE NOT DONE NOT DONE     - 
IRON DEFICIENCY 
ANEMIA 
50 NORMOCYTIC NORMOCHROMIC RBCS WBCS AND PLATELETS NORMAL INCREASED BV MARKINGS NOT DONE ECHO- CONCENTRIC LVH, EF 65 %, 
ANEMIA OF CHRONIC 
DISEASE 
51 MICROCYTIC HYPOCHROMIC ANEMIA LEUCOPENIA PLATELETS ADEQUATE CARDIOMEGALY NOT DONE     - 
IRON DEFICIENCY 
ANEMIA 
52 MICROCYTIC HYPOCHROMIC ANEMIA WBCS AND PLATELETS NORMAL NOT DONE NOT DONE     - 
IRON DEFICIENCY 
ANEMIA 
53 MICROCYTIC HYPOCHROMIC ANEMIA LYMPHOCYTOSIS PLATELETS NORMAL 
BILATERAL PLEURAL 
EFFUSION NOT DONE SPUTUM AFB POSITIVE 
IRON DEFICIENCY 
ANEMIA 
54 MICROCYTIC HYPOCHROMIC ANEMIA LEUCOPENIA PLATELETS ADEQUATE NOT DONE NOT DONE     - 
IRON DEFICIENCY 
ANEMIA 
55 NORMOCYTIC NORMOCHROMIC RBCS WBCS AND PLATELETS NORMAL INCREASED BV MARKINGS NOT DONE 
UGI SCOPY- GRADE II ESOPHAGEAL 
VARICES 
IRON DEFICIENCY 
ANEMIA 
56 NORMOCYTIC NORMOCHROMIC RBCS WBCS AND PLATELETS NORMAL NOT DONE NOT DONE     - 
ANEMIA OF CHRONIC 
RENAL DISEASE 
57 NORMOCYTIC NORMOCHROMIC RBCS WBCS AND PLATELETS NORMAL NOT DONE NOT DONE     - 
ANEMIA OF CHRONIC 
RENAL DISEASE 
58 NORMOCYTIC NORMOCHROMIC RBCS WBCS AND PLATELETS NORMAL NOT DONE NOT DONE     - 
ANEMIA OF CHRONIC 
DISEASE 
59 NORMOCYTIC NORMOCHROMIC RBCS WBCS AND PLATELETS NORMAL 
BILATERAL PLEURAL 
EFFUSION NOT DONE     - 
ANEMIA OF CHRONIC 
RENAL DISEASE 
60 MICROCYTIC HYPOCHROMIC ANEMIA NEUTROPHILIA AND PLATELETS NORMAL INCREASED BV MARKINGS NOT DONE     - 
IRON DEFICIENCY 
ANEMIA 
61 DIMORPHIC ANEMIA WBCS AND PLATELETS NORMAL NOT DONE NOT DONE 
BMA- ERYTHROID HYPERPLASIA 
WITH DIMORPHIC 
ERYTHROPOIESIS 
IRON DEFICIENCY 
ANEMIA 
62 MICROCYTIC HYPOCHROMIC ANEMIA NEUTROPHILIA AND PLATELETS NORMAL NOT DONE NOT DONE URINE CULTURE- E.COLI GROWTH 
IRON DEFICIENCY 
ANEMIA 
63 NORMOCYTIC NORMOCHROMIC ANEMIA WBC AND PLATELETS NORMAL NOT DONE 
L SIDE INFARCT IN MCA 
TERRITORY     - 
ANEMIA OF CHRONIC 
DISEASE 
64 MICROCYTIC HYPOCHROMIC ANEMIA  WBCS AND PLATELETS NORMAL NOT DONE NOT DONE     - 
IRON DEFICIENCY 
ANEMIA 
65 MACROCYTIC RBCS HYPERSEGMENTED NEUTROPHILS PLATELETS ADEQUATE NOT DONE NOT DONE     - 
ANEMIA OF CHRONIC 
RENAL 
DISEASE/B12/FOLATE 
DEF 
66 NORMOCYTIC NORMOCHROMIC ANEMIA NEUTROPHILIA PLATELETS NORMAL NOT DONE NOT DONE     - 
ANEMIA OF CHRONIC 
RENAL  DISEASE 
67 NORMOCYTIC NORMOCHROMIC RBCS WBCS AND PLATELETS NORMAL NOT DONE NOT DONE     - 
ANEMIA OF CHRONIC 
DISEASE 
68 NORMOCYTIC NORMOCHROMIC ANEMIA NEUTROPHILIA PLATELETS NORMAL NORMAL STUDY NOT DONE 
UGI SCOPY GROWTH LOWER ONE 
THIRD ESOPHAGUS BIOPSY 
SQUAMOUS CELL CARCINOMA 
ANEMIA OF CHRONIC 
DISEASE 
69 MILD MICROCYTIC HYPOCHROMIC ANEMIA WBC AND PLATELETS NORMAL NORMAL STUDY NOT DONE     - 
ANEMIA OF CHRONIC 
DISEASE 
70 MILD MICROCYTIC HYPOCHROMIC ANEMIA WBC AND PLATELETS NORMAL NORMAL STUDY NOT DONE UGI SCOPY DUODENAL ULCER 
ANEMIA OF CHRONIC 
DISEASE 
71 NORMOCYTIC NORMOCHROMIC ANEMIA NEUTROPHILIA PLATELETS NORMAL 
OLD CAVITY APICAL  
OPACITIES L LUNG   NOT DONE     - 
ANEMIA OF CHRONIC 
DISEASE 
72 MICROCYTIC HYPOCHROMIC ANEMIA NEUTROPHILIA AND PLATELETS NORMAL 
MINIMAL BILATERAL PLEURAL 
EFFUSION NOT DONE     - 
IRON DEFICIENCY 
ANEMIA 
73 NORMOCYTIC NORMOCHROMIC ANEMIA LYMPHOCYTOSIS PLATELETS NORMAL 
BILATERAL PLEURAL 
EFFUSION NOT DONE SPUTUM AFB POSITIVE 
ANEMIA OF CHRONIC 
DISEASE 
74 MILD MICROCYTIC HYPOCHROMIC ANEMIA LYMPHOCYTOSIS PLATELETS NORMAL 
BILATERAL PLEURAL 
EFFUSION NOT DONE     - 
IRON DEFICIENCY 
ANEMIA 
75 MILD MICROCYTIC HYPOCHROMIC ANEMIA LEUCOCYTOSIS PLATELETS NORMAL NORMAL STUDY NOT DONE URINE CULTURE- E.COLI GROWTH 
ANEMIA OF 
UNEXPLAINED 
ETIOLOGY 
76 MODERATE MICROCYTIC HYPOCHROMIC ANEMIA WBC AND PLATELETS NORMAL NORMAL STUDY NOT DONE     - 
IRON DEFICIENCY 
ANEMIA 
77 NORMOCYTIC NORMOCHROMIC ANEMIA WBC AND PLATELETS NORMAL NORMAL STUDY NOT DONE     - 
IRON DEFICIENCY 
ANEMIA 
78 NORMOCYTIC NORMOCHROMIC ANEMIA WBC AND PLATELETS NORMAL NORMAL STUDY NOT DONE     - 
ANEMIA OF CHRONIC 
RENAL DISEASE 
79 NORMOCYTIC NORMOCHROMIC ANEMIA WBC AND PLATELETS NORMAL 
L INTERTROCHANTERIC 
FRACTURE NOT DONE     - 
IRON DEFICIENCY 
ANEMIA 
80 MODERATE MICROCYTIC HYPOCHROMIC ANEMIA WBC AND PLATELETS INCREASED NORMAL STUDY NOT DONE UGI SCOPY ULCER IN PYLORUS 
IRON DEFICIENCY 
ANEMIA 
81 NORMOCYTIC HYPOCHROMIC ANEMIA WBCS AND PLATELETS NORMAL NORMAL STUDY NOT DONE     - 
ANEMIA OF 
UNEXPLAINED 
ETIOLOGY 
82 MICROCYTIC HYPOCHROMIC ANEMIA WBCS AND PLATELETS NORMAL NORMAL STUDY NOT DONE     - 
IRON DEFICIENCY 
ANEMIA 
83 SEVERE MICROCYTIC HYPOCHROMIC ANEMIA WBCS AND PLATELETS NORMAL NORMAL STUDY 
LEFT THALAMIC 
HEMORRHAGE     - 
IRON DEFICIENCY 
ANEMIA 
84 NORMOCYTIC NORMOCHROMIC ANEMIA NEUTROPHILIA PLATELETS NORMAL NOT DONE MEDIASTINAL MASS 
BRONCHOSCOPY- MASS RIGHT 
BRONCHUS,,BRUSH- SUGGESTIVE 
OF MALIGNANCY 
ANEMIA OF CHRONIC 
DISEASE 
85 MICROCYTIC HYPOCHROMIC ANEMIA NEUTROPHILIA AND PLATELETS NORMAL 
BILATERAL PLEURAL 
EFFUSION NOT DONE     - 
IRON DEFICIENCY 
ANEMIA 
86 NORMOCYTIC NORMOCHROMIC ANEMIA WBC AND PLATELETS NORMAL NORMAL STUDY NORMAL STUDY     - 
IRON DEFICIENCY 
ANEMIA 
87 NORMOCYTIC NORMOCHROMIC ANEMIA WBC AND PLATELETS NORMAL NORMAL STUDY NOT DONE     - 
ANEMIA OF CHRONIC 
DISEASE 
88 MICROCYTIC HYPOCHROMIC ANEMIA WBCS AND PLATELETS NORMAL NORMAL STUDY NORMAL STUDY     - 
IRON DEFICIENCY 
ANEMIA 
89 MICROCYTIC HYPOCHROMIC ANEMIA WBCS AND PLATELETS NORMAL NORMAL STUDY NOT DONE     - 
IRON DEFICIENCY 
ANEMIA 
90 NORMOCYTIC NORMOCHROMIC ANEMIA NEUTROPHILIA PLATELETS NORMAL NORMAL STUDY NOT DONE 
FNAC INGUINAL NODE- 
CARCINOMATOUS METASTATIC 
DEPOSITS 
ANEMIA OF CHRONIC 
DISEASE 
91 
MICROCYTIC HYPOCHROMIC ANEMIA BLASTS 23%, 
SEGMENTED 23% LYMPH 32% BASO 12% PL- 
NORMAL 
NORMAL STUDY NOT DONE     - ANEMIA OF CHRONIC DISEASE 
92 NORMOCYTIC NORMOCHROMIC ANEMIA WBC AND PLATELETS NORMAL NOT AVAILABLE NOT DONE     - 
ANEMIA OF 
UNEXPLAINED 
ETIOLOGY 
93 NORMOCYTIC NORMOCHROMIC ANEMIA WBC AND PLATELETS NORMAL NORMAL STUDY 
PARAAORTIC NODES 
ENLARGED     - 
ANEMIA OF CHRONIC 
DISEASE 
94 NORMOCYTIC NORMOCHROMIC ANEMIA WBC AND PLATELETS NORMAL NOT DONE NOT DONE     - 
ANEMIA OF CHRONIC 
DISEASE 
95 MICROCYTIC HYPOCHROMIC ANEMIA WBCS AND PLATELETS NORMAL NOT DONE NOT DONE     - 
IRON DEFICIENCY 
ANEMIA 
96 DIMORPHIC ANEMIA WBCS AND PLATELETS NORMAL NOT DONE NOT DONE 
FNAC BREAST MASS- DUCTAL 
CARCINOMA GRADE III,,NODE- 
METASTATIC CARCINOMATOUS 
DEPOSITS 
ANEMIA OF CHRONIC 
DISEASE 
97 MICROCYTIC HYPOCHROMIC ANEMIA WBCS AND PLATELETS NORMAL NOT DONE BRAIN NORMAL STUDY     - 
IRON DEFICIENCY 
ANEMIA 
98 MICROCYTIC NYPOCHROMIC ANEMIA WBCS AND PLATELETS NORMAL NOT AVAILABLE NOT DONE     - 
IRON DEFICIENCY 
ANEMIA 
99 MICROCYTIC NYPOCHROMIC ANEMIA WBCS AND PLATELETS NORMAL BILATERAL BRONCHIECTASIS NOT DONE     - 
IRON DEFICIENCY 
ANEMIA 
100 MICROCYTIC NYPOCHROMIC ANEMIA WBCS AND PLATELETS NORMAL CARDIOMEGALY NOT DONE 
LEFT VENTRICULAR 
HYPERTROPHY 
ANEMIA OF CHRONIC 
DISEASE 
 
